<SEC-DOCUMENT>0001683168-23-003132.txt : 20230511
<SEC-HEADER>0001683168-23-003132.hdr.sgml : 20230511
<ACCEPTANCE-DATETIME>20230510173405
ACCESSION NUMBER:		0001683168-23-003132
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230511
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RadNet, Inc.
		CENTRAL INDEX KEY:			0000790526
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				133326724
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33307
		FILM NUMBER:		23907918

	BUSINESS ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025
		BUSINESS PHONE:		3104787808

	MAIL ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIMEDEX HEALTH SYSTEMS INC
		DATE OF NAME CHANGE:	19930518

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCC FRANCHISING CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>radnet_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:RDNT="http://radnet.com/20230509">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_RDNT_radnet.com_20230509 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20230509_20230509 -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0000790526 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:EntityCentralIndexKey">0000790526</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rdnt-20230509.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-05-09to2023-05-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000790526</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-09</xbrli:startDate>
        <xbrli:endDate>2023-05-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">UNITED
STATES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Washington,
D.C. 20549</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20230509__20230509_z1FITdfpaI49"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date
of Report (Date of earliest event reported <span id="xdx_908_edei--DocumentPeriodEndDate_c20230509__20230509_zbW2WsGOP0fg"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 9, 2023</ix:nonNumeric></span></span>)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">_______________________________________________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90E_edei--EntityRegistrantName_c20230509__20230509_zRECoEPY1Svl" style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:EntityRegistrantName">RadNet,
Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 10pt; width: 32%"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20230509__20230509_zefyDHC0HyZ9" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 10pt; width: 32%"><span id="xdx_90C_edei--EntityFileNumber_c20230509__20230509_zKSH9AfseYa" style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:EntityFileNumber">001-33307</ix:nonNumeric></b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 32%"><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20230509__20230509_ze8qLjsYGFu4" style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:EntityTaxIdentificationNumber">13-3326724</ix:nonNumeric></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">(State or other jurisdiction<br />
    of incorporation)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(IRS Employer Identification No.)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 48%"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20230509__20230509_zoQmXhgqi2kh"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:EntityAddressAddressLine1">1510 Cotner Avenue</ix:nonNumeric></span></b></td>
  <td style="width: 4%">&#160;</td>
  <td style="text-align: center; width: 48%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1pt solid; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20230509__20230509_zIw1KX8uwQp9"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:EntityAddressCityOrTown">Los
  Angeles</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20230509__20230509_zMDS6WHPEOL8"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: center"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20230509__20230509_zSRqAMYyUjL4"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:EntityAddressPostalZipCode">90025</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center">(Address of Principal Executive Offices)</td>
  <td>&#160;</td>
  <td style="text-align: center">(Zip Code)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Registrant&#8217;s
Telephone Number, Including Area Code: <b>(<span id="xdx_908_edei--CityAreaCode_c20230509__20230509_zhZxAtuopuv7"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:CityAreaCode">310</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20230509__20230509_zO3cESiMevMf"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:LocalPhoneNumber">478-7808</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(Former name or former
address, if changed since last report.)</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span id="xdx_90A_edei--WrittenCommunications_c20230509__20230509_zb3PekmLUhUi" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span id="xdx_901_edei--SolicitingMaterial_c20230509__20230509_zIKYjzsz3yAb" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span id="xdx_905_edei--PreCommencementTenderOffer_c20230509__20230509_zjWYD8LEpZ54" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span id="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20230509__20230509_zFYZw03L3nZ1" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
                                            of each class</b></span></p></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span id="xdx_903_edei--Security12bTitle_c20230509__20230509_zEeI2pVlLTE6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value</ix:nonNumeric></span></td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_90E_edei--TradingSymbol_c20230509__20230509_zfJsuDT9Frqh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" name="dei:TradingSymbol">RDNT</ix:nonNumeric></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span id="xdx_903_edei--SecurityExchangeName_c20230509__20230509_zo4Uca94bAzf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ
    Global Market</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20230509__20230509_zD2RlamTUDmb"><ix:nonNumeric contextRef="From2023-05-09to2023-05-09" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in">Item 2.02</td><td>RESULTS OF OPERATIONS AND FINANCIAL CONDITION</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 9, 2023 RadNet, Inc.
(&#8220;RadNet&#8221;) issued a press release and held a conference call regarding its 2023 financial results for the first quarter ended
March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 and a copy of the transcript of the conference call is furnished
as Exhibit 99.2 to this Current Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this Current
Report, including Exhibit 99.1 and Exhibit 99.2 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report,
including Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any registration statement or other document filed
with the Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 1in"><b>Item 9.01.</b></td>
  <td><b>FINANCIAL STATEMENTS AND EXHIBITS.</b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34pt">(d)<span style="font-size: 10pt"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</b></span>Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 18%"><span style="text-decoration: underline"><b>Exhibit Number</b></span></td>
    <td style="width: 82%"><span style="text-decoration: underline"><b>Description of Exhibit</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>99.1</td>
    <td style="text-align: justify"><a href="radnet_ex9901.htm">Press Release dated May 9, 2023 relating to RadNet, Inc.&#8217;s financial results for the first quarter ended March 31, 2023.</a></td></tr>
  <tr style="vertical-align: top">
    <td>99.2</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"><a href="radnet_ex9902.htm">Transcript of conference call.</a></p>
</td></tr>
  <tr style="vertical-align: top">
    <td>104</td>
    <td>Cover Page Interactive Data File (embedded within the inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34pt"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>RADNET, INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">Date: May 10, 2023</td>
    <td style="width: 5%">By:</td>
    <td style="border-bottom: Black 1pt solid; width: 45%">/s/ Mark D. Stolper</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Name:</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark D. Stolper</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Title:</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</p></td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td><b><span style="text-decoration: underline">Exhibit No.</span></b></td><td style="text-align: justify"><b><span style="text-decoration: underline">Description</span></b></td></tr>
                                                                                                                                          <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                          <tr style="vertical-align: top">
<td style="width: 1in"><b>99.1</b></td><td style="text-align: justify"><a href="radnet_ex9901.htm"><b>Press Release dated May 9, 2023.</b></a></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                  <tr style="vertical-align: top">
<td><b>99.2<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></b></td><td style="text-align: justify"><a href="radnet_ex9902.htm"><b>Transcript of conference call.</b></a></td></tr>
                                                                                                                                                  <tr style="vertical-align: top">
<td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                                  <tr style="vertical-align: top">
<td>104</td><td style="text-align: justify">Cover Page Interactive Data File (embedded within the inline XBRL document)</td></tr>
                                                                                                                                                  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LdpNBbdLh4o4ZYwh3hYXpbg1I61/j+Rb2m2IIRCSc74cIUZiQ2tdI8NpWWRQYtPWyiEUeEFGc0bvSLe7BPws8KqtY2Vcv/7AlDyDnpmPY+XvvfOhLVYJyMVExpMoBDlL5BTyvQg6PSVz0RUap1UNylSQM7Ws0Sl+Dx9K9SJDzbtPOiJbTSaBcCwH+QORDCM40EM9iW8WsiwVwaivQGyY7m0Xc7eOGljV2PgsO6D/Dr7iWkkg -->

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>radnet_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: red"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 74.25pt; width: 172.5pt"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 12pt"><B>RadNet Reports First Quarter Financial
Results with Record First Quarter Revenue and Adjusted EBITDA<SUP>(1)</SUP> from Imaging Center Operations and Revises Upwards 2023 Financial
Guidance Ranges for Revenue and Adjusted EBITDA<SUP>(1)</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Revenue increased 14.3% to $390.6 million in the first quarter of 2023
from $341.8 million in the first quarter of 2022; Excluding Revenue from our Artificial Intelligence (&ldquo;AI&rdquo;) reporting segment,
Revenue from the Imaging Center segment in the first quarter of 2023 was $388.4 million, an increase of 13.9% from last year&rsquo;s first
quarter of $341.2 million</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext"><I>Excluding losses from our AI reporting segment, Adjusted
EBITDA<SUP>(1)</SUP> from Imaging Centers was $52.7 million in the first quarter of 2023 as compared with $41.7 million in the first quarter
of 2022, an increase of 26.2%; Adjusted EBITDA<SUP>(1)</SUP>, including losses from our AI reporting segment, was $48.2 million in the
first quarter of 2023 as com</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">pared with $38.1 million
in the first quarter of 2022, an increase of 26.3%</FONT></I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><I>Adjusting for unusual or one-time items impacting Net Loss
in the quarter, Adjusted Loss Per Share<SUP>(3)</SUP> was $(0.08) for the first quarter of 2023; This compares with Adjusted Loss Per
Share<SUP>(3)</SUP> of $(0.13) for the first quarter of 2022 </I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Aggregate procedural volumes increased 14.0% and same-center procedural
volumes increased 9.3% compared with the first quarter of 2022</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>RadNet revises full-year 2023 guidance levels to increase Revenue and
Adjusted EBITDA<SUP>(1)</SUP> ranges</I></FONT></TD></TR></TABLE>

<P STYLE="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LOS ANGELES, California, May 9, 2022 &ndash;
RadNet, Inc. (NASDAQ: RDNT),</B> <FONT STYLE="color: black">a national leader in providing high-quality, cost-effective, fixed-site outpatient
diagnostic imaging services through a network of 363 owned and operated outpatient imaging centers</FONT>, today reported financial results
for its first quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer of RadNet, commented, &ldquo;I am very pleased with the continuing strength of our core imaging center business. In our Imaging
Center operating segment, Revenue increased almost 14% and Adjusted EBITDA<SUP>(1)</SUP> increased over 25% from last year&rsquo;s first
quarter. Our procedural volumes both on an aggregate and same-center basis demonstrated strong growth, in a quarter that is seasonally
our weakest. Though the cost and availability of labor continues to be challenging, we are having more success in filling open positions
and retaining talented team members.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Given the positive trends we are experiencing
in our core business and the strong financial performance of the first quarter, we have elected to revise certain guidance levels upwards
in anticipation of financial results that we believe will exceed our original expectations. We have increased 2023 guidance ranges for
Revenue and Adjusted EBITDA<SUP>(1)</SUP>,&rdquo; added Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger continued, &ldquo;We are executing
on all facets of our strategic plan. In response to the heavy demand we are experiencing in our core imaging center geographies, we are
in process of growing capacity and access through the de novo strategy we embarked on last year. We also continue to grow our joint venture
offerings through establishing new health system partnerships and the expansion of existing ones. Furthermore, we believe that market
pressures from a challenging environment for labor, significant rising interest rates and a lack of availability of capital could accelerate
acquisition opportunities in an industry that remains highly fragmented and that is mainly comprised of smaller operators who lack the
economies of scale that we have achieved. We also continue to make strides in AI that should materially enhance the accuracy, efficiency
and margin profile of our service offerings in the coming years. In the coming quarters, we will be expanding our roll-out of the Enhanced
Breast Cancer Detection (EBCD) program we launched in November of last year, powered by our DeepHealth AI technologies, and we continue
to innovate new features and capabilities of our AI engines for breast, lung and prostate imaging.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2023, RadNet reported
Revenue from its Imaging Center reporting segment of $388.4 million and Adjusted EBITDA<SUP>(1)</SUP>, excluding Losses from AI reporting
segment, of $52.7 million. Revenue increased $47.3 million (or 13.9%) and Adjusted EBITDA<SUP>(1)</SUP>, excluding Losses from the AI
reporting segment, increased $10.9 million (or 26.2%). Including our AI reporting segment Revenue of $2.1 million, Revenue was $390.6
million in the first quarter of 2023, an increase of 14.3% from $341.8 million in last year&rsquo;s first quarter. Unadjusted for AI reporting
segment Adjusted EBITDA<SUP>(1)</SUP> losses of $4.5 million in the first quarter of 2023 and $3.6 million in the first quarter of 2022,
Adjusted EBITDA<SUP>(1) </SUP>for the first quarter of 2023 was $48.2 million as compared with $38.1 million in the first quarter of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Loss for the first quarter of 2023 was $21.0
million as compared with a Diluted Net Income of $3.0 million for the first quarter of 2022. Net Loss Per Share <FONT STYLE="color: black">for
the first quarter of 2023 was $(0.36), compared with a Diluted Net Income per share of $0.05 in the first quarter of 2022, based upon
a weighted average number of diluted shares outstanding of 57.7 million shares in 2023 and 56.4 million shares in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">There were a number
of unusual or one-time items impacting the first quarter including: </FONT>$4.1 million of non-cash loss from interest rate swaps; <FONT STYLE="color: black">$959,000
expense related to leases for our de novo facilities under construction that have yet to open their operations; $1.6 million non-cash
increase to contingent consideration related to completed acquisitions; $719,000 expense related to the re-valuation of holdbacks related
to completed acquisitions; and $7.6 million of net pre-tax expenses related to our AI division. Adjusting for the above items, Adjusted
Loss<SUP>(3)</SUP> from the Imaging Center reporting segment was $4.7 million and diluted Adjusted Loss Per Share<SUP>(3)</SUP> was $(0.08)
during the first quarter of 2023. This compares with Adjusted Loss<SUP>(3)</SUP> from the Imaging Center reporting segment of $7.6 million
and diluted Adjusted Loss Per Share<SUP>(3)</SUP> of $(0.13) during the first quarter of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Also affecting Net
Income in the first quarter of 2023 were certain non-cash expenses and unusual items including: $12.2 million of non-cash employee stock
compensation expense resulting from the vesting of certain options and restricted stock; </FONT>$134,000 of severance paid in connection
with headcount reductions related to cost savings initiatives; and <FONT STYLE="color: black">$746,000 of non-cash amortization of deferred
financing costs and loan discounts related to financing fees paid as part of our existing credit facilities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2023, as compared with
the prior year&rsquo;s first quarter, MRI volume increased 16.7%, CT volume increased 16.8% and PET/CT volume increased 20.9%. Overall
volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 14.0% over the
prior year&rsquo;s first quarter. On a same-center basis, including only those centers which were part of RadNet for both the first quarters
of 2023 and 2022, MRI volume increased 11.9%, CT volume increased 10.6% and PET/CT volume increased 20.5%. Overall same-center volume,
taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 9.3% over the prior
year&rsquo;s same quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>2023 Revised Guidance</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RadNet amends its previously announced guidance
levels as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><U>Imaging Center Segment</U></FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 25%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><U>Original Guidance Range</U></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><U>Revised Guidance Range</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-size: 10pt">Revenue</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$1,525 million - $1,575 million</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$1,550 million - $1,600 million</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Adjusted EBITDA<SUP>(1)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$220 million - $230 million</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$225 million - $235 million</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-size: 10pt">Capital Expenditures <SUP>(a)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$105 million - $115 million</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$110 million - $120 million</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Cash Paid for Interest <SUP>(c)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$35 million - $40 million</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$45 million - $50 million</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-size: 10pt">Free Cash Flow Generation <SUP>(b)(2)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$70 million - $80 million</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$65 million - $70 million</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><U>Artificial Intelligence Segment</U></FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: right; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right; width: 25%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><U>Original Guidance Range</U></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><U>Revised Guidance Range</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-size: 10pt">Revenue</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$16 million - $18 million</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Unchanged</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Adjusted EBITDA<SUP>(1)</SUP> (Loss)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$(9) million - $(11) million</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Unchanged</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<BR></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2%"></TD><TD STYLE="width: 3%">(a)</TD><TD STYLE="text-align: justify; width: 95%">Net of proceeds from the sale of equipment, imaging centers and joint venture interests, and excludes
New Jersey Imaging Network capital expenditures.</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Defined by the Company as Adjusted EBITDA</FONT><SUP>(1)</SUP> <FONT STYLE="font-size: 10pt">from
Imaging Center Segment less Capital Expenditures and Cash Paid for Interest.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>(c)</TD><TD STYLE="text-align: justify">Net of payments to and from counterparties on interest rate swaps.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Berger highlighted,
&ldquo;We have increased our guidance ranges for Revenue and Adjusted EBITDA</FONT><FONT STYLE="color: black"><SUP>(1)</SUP></FONT> <FONT STYLE="font-size: 10pt">to
reflect the first quarter&rsquo;s strong financial results as compared with our original budget. Though we remain vigilant about the economic
environment, supply chain disruptions, inflation and the possibility of further variants of COVID-19, we have opportunities to expand
our operations in all of our markets both organically and through new acquisitions and joint ventures. We also are increasing our guidance
levels for cash interest expense and capital expenditures to account for both the rising cost of interest on that portion of our debt
which is not subject to our interest rate swaps and to fund the completion of certain of our de novo facilities scheduled to open during
the remainder of 2023 and the first half of 2024.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call for Today</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its first quarter
2023 results on Tuesday, May 9th, 2023 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conference Call Details:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: Tuesday, May 9, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time: 10:30 a.m. Eastern Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dial In-Number: 844-826-3035</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">International Dial-In Number: 412-317-5195</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">It is recommended
that participants dial in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and
archived webcasts available at </FONT>https://viavid.webcasts.com/starthere.jsp?ei=1612864&amp;tp_key=c9dd50c578 <FONT STYLE="font-size: 10pt">or
http://www.radnet.com under the &ldquo;Investors&rdquo; menu section and &ldquo;News Releases&rdquo; sub-menu of the website. An archived
replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international
callers, and using the passcode 10178605.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>About RadNet, Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">RadNet, Inc. is the leading national provider
of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.
RadNet has a network of 363 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware,
New Jersey, New York, Florida and Arizona. In addition, RadNet provides radiology information technology and artificial intelligence solutions,
teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together
with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,000 employees.
For more information, visit http://www.radnet.com.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Forward Looking Statements</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and
strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified
by words such as: &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;goal,&rdquo; &ldquo;seek,&rdquo; &ldquo;believe,&rdquo;
&ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;strategy,&rdquo; &ldquo;future,&rdquo; &ldquo;likely,&rdquo;
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; and similar references to future periods. Forward-looking statements in this
press release include, among others, statements we make regarding response to and the expected future impacts of COVID-19, including statements
about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to
service or refinance our current indebtedness.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are neither historical
facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties,
risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and
financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue
reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking statements include, among others, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of a pandemic, significant deterioration
in the broader economy, severe acts of nature or other exogenous factors on our business, suppliers, payors, customers, referral sources,
partners, patients and employees;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability and terms of capital to fund
our business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to service our indebtedness, make
principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our
ability to refinance such indebtedness on acceptable terms;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in general economic conditions nationally
and regionally in the markets in which we operate;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability and terms of capital to fund
the expansion of our business and improvements to our existing facilities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to maintain our current credit rating
and the impact on our funding costs and competitive position if we do not do so;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">our ability to acquire, develop, implement and monetize artificial intelligence
algorithms and applications;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">volatility in interest and exchange rates, or
credit markets;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the adequacy of our cash flow and earnings to
fund our current and future operations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in service mix, revenue mix and procedure
volumes; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in receiving payments for services provided;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">increased bankruptcies among our partner physicians
or joint venture partners;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of the political environment and related
developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;
</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the extent to which the ongoing implementation
of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or
related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">closures or slowdowns and changes in labor costs
and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in
our facilities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the occurrence of hostilities, political instability
or catastrophic events; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the emergence or reemergence of and effects related
to future pandemics, epidemics and infectious diseases; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">noncompliance by us with any privacy or security
laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized
use or disclosure of confidential information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any forward-looking statement contained in this
current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of
changed circumstances, new information, future developments or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation G: GAAP and Non-GAAP Financial
Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release contains certain financial information
not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes
that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes
this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in
the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should
not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled
measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial
information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this
release in the tables which follow.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>CONTACTS: </I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>RadNet, Inc.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mark Stolper, 310-445-2800</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Executive Vice President and Chief Financial
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">90,844</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">127,834</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">166,357</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Due from affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,387</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,971</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">55,100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54,022</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">342,685</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">367,184</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">545,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">565,961</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Operating lease right-of-use assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">623,309</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">603,524</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total property, equipment and right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,168,801</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,169,485</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">687,085</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">677,665</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Other intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,003</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,228</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,122</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,280</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Investment in joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,321</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,893</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Deposits and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">51,052</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,172</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 30pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,414,069</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,433,907</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accounts payable, accrued expenses and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">296,727</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">369,595</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Due to affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,548</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,100</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Current operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,590</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,607</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Current portion of notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,935</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,400</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">407,143</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">466,723</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">LONG-TERM LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Long-term operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">623,538</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">604,117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Notes payable, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">852,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">839,344</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Deferred tax liability, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,410</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,256</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Other non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,523</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,015</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 30pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,920,968</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,942,455</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">RadNet, Inc. stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock - $0.0001 par value, 200,000,000 shares authorized; 58,270,290 and 57,723,125 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">448,522</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">436,288</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,978</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,677</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(103,628</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(82,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total RadNet, Inc.'s stockholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">327,922</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">332,995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">165,179</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">158,457</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">493,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">491,452</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,414,069</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,433,907</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">REVENUE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Service fee revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">352,420</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">303,276</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Revenue under capitation arrangements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38,144</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38,491</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Total service revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390,564</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">341,767</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Cost of operations, excluding depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">351,865</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,039</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,118</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Loss on sale and disposal of equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Severance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">201</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: 400; font-style: normal; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">383,893</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">343,486</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) FROM OPERATIONS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,719</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OTHER INCOME AND EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,722</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,593</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,428</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,517</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,819</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,432</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total other expense (income)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,819</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,578</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">(LOSS) INCOME BEFORE INCOME TAXES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,148</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,859</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,135</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,496</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">NET (LOSS) INCOME</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,283</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,363</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Net income attributable to noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,722</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,350</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">NET (LOSS) INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(21,005</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,013</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">BASIC NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.05</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">DILUTED NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.05</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">57,701,439</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">55,303,007</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">57,701,439</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">56,362,193</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; text-indent: -10pt; padding-left: 20pt">Net (loss) income</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(14,283</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">8,363</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,118</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Amortization of operating lease assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,699</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,802</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Equity in earnings of joint ventures, net of dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,835</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,517</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Amortization deferred financing costs and loan discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">648</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Loss on sale and disposal of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Amortization of cash flow hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">922</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">923</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,819</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,185</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,102</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Change in fair value of contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(501</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 40pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,997</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,904</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 40pt">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,691</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,065</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 40pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,726</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,417</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 40pt">Deferred taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">942</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,387</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 40pt">Operating leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,080</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,859</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 40pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,519</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 40pt">Accounts payable, accrued expenses and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,077</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,031</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 50pt">Net cash provided by operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,616</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">901</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Purchase of imaging facilities and other acquisitions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,644</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,123</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Purchase of property and equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,915</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,558</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Proceeds from sale of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 50pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(65,556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(61,564</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Principal payments on notes and leases payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Payments on Term Loan Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,688</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,313</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Proceeds from issuance of common stock upon exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">51</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 50pt">Net cash used in financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,821</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,313</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(229</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">NET DECREASE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,990</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(63,893</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">CASH AND CASH EQUIVALENTS, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">127,834</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">134,606</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">CASH AND CASH EQUIVALENTS, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">90,844</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">70,713</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Cash paid during the period for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">21,471</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,448</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Cash paid during the period for income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">34</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>RADNET,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center; background-color: white"><B>RECONCILIATION
OF GAAP NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA<SUP>(1)</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: center; background-color: white"><B>(IN THOUSANDS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Net (loss) income attributable to RadNet, Inc. common stockholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(21,005</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,013</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,135</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,496</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,722</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,593</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Severance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">201</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,118</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-cash employee stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,185</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,102</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Loss on sale and disposal of equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,819</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Other expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,432</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal settlements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,616</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Non operational rent expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">959</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">938</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 20pt">Adjusted EBITDA Including Losses from AI Segment and Provider relief funding</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">48,165</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">38,132</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">EBITDA Losses from AI Segment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,496</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,585</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA excluding Losses from AI Segment and Provider relief funding</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">52,661</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">41,717</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PAYOR CLASS BREAKDOWN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 52%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">First Quarter</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 35%; text-align: left">Commercial Insurance</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">58.1%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicare</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22.2%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Capitation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.8%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicaid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.6%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Workers Compensation/Personal Injury</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.2%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.1%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>RADNET PAYMENTS BY MODALITY</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">First Quarter</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%">MRI</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">36.4%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">36.8%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">36.0%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">35.4%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.2%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.5%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.2%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.6%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>PET/CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.8%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.8%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.5%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>X-ray</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.4%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.7%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.9%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.3%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Ultrasound</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.8%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.7%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.3%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mammography</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.3%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.1%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.7%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Nuclear Medicine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.8%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.9%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.6%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.5%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.6%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.7%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>PROCEDURES BY MODALITY*</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 69%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">First Quarter</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">First Quarter</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 35%">MRI</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">369,556</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">316,784</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,379</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">196,461</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>PET/CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,126</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,683</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Nuclear Medicine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,457</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Ultrasound</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">608,986</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">525,569</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mammography</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">455,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">410,807</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">X-ray and Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">817,851</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">726,424</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,504,635</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,197,185</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Volumes include wholly owned and joint venture centers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE <FONT STYLE="font: normal 700 10pt Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2"> </TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">NET (LOSS) INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">(21,005</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; text-align: right">3,013</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Subtract non-cash change in fair value of interest rate hedges (i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,819</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Legal Settlement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Non-operational rent expenses (iii)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">938</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,616</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Holdback Re-valuation Adjustments - Quantib and Heart &amp; Lung Health</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">719</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">AI Segment Losses (iv)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,593</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total adjustments - loss (gain)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,980</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,571</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Subtract tax impact of Adjustments (ii)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,980</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt">Tax effected impact of adjustments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,591</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">TOTAL ADJUSTMENT TO NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,273</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,591</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">ADJUSTED NET LOSS ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,732</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,578</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,701,439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,362,193</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">ADJUSTED DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 4%; vertical-align: top">(i) </TD>
    <TD STYLE="text-align: justify; width: 96%">Impact from the change in fair value of the hedges during the quarter.&nbsp;&nbsp;Excludes the amortization of the accumulation of the changes in fair value out of Other Comprehensive Income that existed prior to the hedges becoming ineffective.</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">(ii)</TD>
    <TD STYLE="text-align: justify"> Tax effected using 15.8% and -8.63% blended federal and state effective tax rate for the first quarter of 2022 and 2023, respectively.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">(iii)</TD>
    <TD> Represents rent expense associated with de novo sites under construction prior to them becoming operational.</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">(iv)</TD>
    <TD> Represents losses before income taxes from Artificial Intelligence reporting segment.</TD>
    </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U><BR STYLE="clear: both">
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Footnotes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(1)</SUP>
The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations
and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation.
Adjusted EBITDA</FONT> includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling
interests in subsidiaries<FONT STYLE="color: windowtext">, and is adjusted for non-cash or extraordinary and one-time events taken place
during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted EBITDA is reconciled to its nearest comparable
GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare
industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not
be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a
measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented,
may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(2)</SUP>
As noted above, the Company defines Free Cash Flow as </FONT>Adjusted EBITDA less total Capital Expenditures (whether completed with cash
or financed) and Cash Interest paid. <FONT STYLE="color: windowtext">Free Cash Flow is a non-GAAP financial measure. </FONT>The Company
uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity
to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows
generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Free Cash Flow should not be considered a measure
of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives
to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the
consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined
in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable
to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>(3)</SUP> The Company defines Adjusted Earnings
(Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders and excludes losses or gains on the disposal of
equipment, loss on debt extinguishments, bargain purchase gains, severance costs, loss on impairment, loss or gain on swap valuation,
gain on extinguishment of debt, unusual or non-recurring entries that impact the Company&rsquo;s tax provision and any other non-recurring
or unusual transactions recorded during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted Earnings (Loss) Per Share is reconciled
to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per Share is a non-GAAP financial measure used as analytical
indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered
a measure of financial performance under GAAP, and the items excluded from Adjusted Earnings Per Share should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted Earnings Per Share
is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as
presented, may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>radnet_ex9902.htm
<DESCRIPTION>TRANSCRIPT OF CONFERENCE CALL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #00339A">&nbsp;<IMG SRC="image_003.jpg" ALT=""><BR STYLE="clear: both">
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #00339A"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 44px; width: 700px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O R P O R A T E P A R T I
C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper, </B><I>Executive Vice President
and Chief Financial Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger, MD, </B><I>President and
Chief Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O N F E R E N C E C A L L
P A R T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut, </B><I>Jefferies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom, </B><I>Raymond James</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow, </B><I>CJS Securities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>P R E S E N T A T I O N</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, and welcome to RadNet, Inc. First
Quarter 2023 Financial Results Call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All participants will be in a listen-only mode.
(Operator Instructions). Please note, this event is being recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would now like to turn the conference over to
Mark Stolper, Executive Vice President and Chief Financial Officer at RadNet, Inc. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, ladies and gentlemen, and thank
you for joining Dr. Howard Berger and me today to discuss RadNet&rsquo;s first quarter 2023 results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we begin today, we'd like to remind everyone
of the Safe Harbor statement under the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning anticipated future
financial and operating performance, RadNet&rsquo;s ability to continue to grow the business by generating patient referrals and contracts
with radiology practices, recruiting and retaining technologists, receiving third-party reimbursement for diagnostic imaging services,
successfully integrating acquired operations, generating revenue and Adjusted EBITDA for the acquired operations as estimated among others
are forward-looking statements within the meaning of the Safe Harbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on Management's
current preliminary expectations and are subject to risks and uncertainties, which may cause RadNet&rsquo;s actual results to differ materially
from the statements contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These risks and uncertainties include those risks
set forth in RadNet&rsquo;s reports filed with the SEC from time to time, including RadNet's Annual Report on Form 10-K for the year ended
December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Undue reliance should not be placed on forward-looking
statements, especially guidance on future financial performance, which speaks only as of the date it is made. RadNet undertakes no obligation
to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or
to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, I'd like to turn the call over to Dr.
Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, everyone, and thank you for joining
us today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On today's call, Mark and I plan to provide you
with highlights from our first quarter 2023 results, give you more insight into factors which affected this performance and discuss our
future strategy. After our prepared remarks, we will open the call to your questions. I'd like to thank all of you for your interest in
our company and for dedicating a portion of your day to participate in our conference call this morning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let's begin. I am very pleased with our performance
in the first quarter. It was the strongest first quarter in our company's history with record revenue and EBITDA. Relative to last year's
first quarter, our core imaging center segment revenue increased 13.9% and imaging center EBITDA increased 26.2% from last year's first
quarter. This strong performance resulted in improved EBITDA margins increasing from 12.2% in the first quarter of 2022 to 13.6% in the
first quarter of 2023, an improvement of 140 basis points. This improvement was the combination of strong volumes, careful management
of expenses, and an improving labor market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to volumes, we are experiencing heavy
demand in virtually all of our markets. Aggregate procedural volumes increased 14.0% and same center procedural volumes increased 9.3%
compared with the first quarter of 2022. This performance is the result of a combination of several factors. First, the aging and growing
population in our markets is driving increasing utilization for diagnostic imaging services. As people age, we rely on diagnostic imaging
with greater frequency. On average, for example, senior and Medicare patients utilize imaging two to three times more frequently than
patients under the age of 65. As baby boomers continue to age and life expectancy continues to increase, we expect this utilization trend
to continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Second, technology in our industry continues to
evolve and improve, creating additional medical indications for ordering diagnostic imaging procedures. Advances in MRI technology and
post-processing software have shortened scanning times and improved image quality. New contrast materials and radioactive pharmaceuticals
are driving novel applications such as PMSA or prostate-specific membrane antigen, PET scans, and Alzheimer's imaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, and perhaps most significant, we are benefiting
from a shift in sight of care. More and more outpatient volumes are being shifted from hospital-based facilities towards free-standing
outpatient facilities where the cost to patients and the insurance companies are substantially less. Not only is the cost lower, but we
strongly believe the quality and the patient experience is improved in well-run outpatient facilities like the ones we operate. We do
not see an end in sight to these industry trends that are driving procedural volumes and believe that these trends will continue to help
drive our consistent same-store performance for years to come.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the labor front, we are experiencing some stability
and improvement. We have been more successful in filling open positions and have been reducing our reliance on expensive temporary staffing
services and overtime hours of our existing team members. While attracting new talent and retaining our existing employee base remains
challenging, we are no longer being plagued by service interruptions from staffing issues like those we faced for most of last year. We
have seen a 12% reduction in open positions since the end of the fourth quarter of last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While hiring and retaining technologists remains
our biggest challenge, we have been refining and increasing our visibility in the marketplace by repositioning our brand, utilizing our
scale and the industry leadership to better leverage partnerships with local trade schools and colleges, and have been adjusting compensation
practices to meet the demands of the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are engaging in direct mailing campaigns, partnering
with accrediting bodies to identify qualified candidates, hosting open houses and hiring events, and instituting incentives such as referral
payments inside and on bonuses. There has been no magic formula for success. However, these grassroot efforts are slowly paying dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the strong performance in this
year's first quarter and the confidence we are feeling from the remainder of the year, we have elected to increase key financial guidance
levels for 2023. Though we remain vigilant about the economic environment, labor shortages, supply chain disruptions, inflation, and COVID-19,
we are executing on opportunities to expand operations in all of our markets, both organically and through new acquisitions and joint
ventures, resulting in what we believe will be stronger results for the year than originally projected. Mark in his prepared remarks will
review the increases we've made to our revenue and EBITDA guidance levels upon releasing our financial results this morning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Twenty twenty-three will also be a year of reinvestment
in our business to accelerate future growth. We currently have 13 de novo facilities in various stages of development, which will open
for operations in the second half of 2023 and throughout 2024. These facilities are located in markets where we have patient backlogs,
require additional capacity or in locations where we currently lack access points to service identified patient populations. Six of these
de novo facilities are scheduled to open in the second half of 2023 and early 2024, and another seven facilities should be producing revenue
in the second half of next year. While these projects are requiring us to make capital investments above our normal spending, we are confident
that these centers will be material contributors to our long-term performance and growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to grow our hospital and health system
joint venture business. Currently, 121 of our 363 centers or 33% are held within health system partnerships. Our partners are some of
the strongest and most successful systems in our geographies. Partners include RWJBarnabas, MemorialCare, Dignity Health, LifeBridge,
University of Maryland Medical System, Adventist, Cedars-Sinai and others. These and other health systems are seeking solutions for long-term
strategies around outpatient imaging and have recognized that cost effective and efficient free-standing centers will continue to capture
market share from hospitals as payers and patients migrate their site of care towards lower cost high quality solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are in the process of expanding our joint venture
business with both existing as well as new health systems. We expect that by year end, our joint venture centers could represent closer
to 40% of our total center count, and we believe that we could reach 50% in the coming years. Our hospital and health system partners
have been instrumental in increasing our procedural volumes through influence on their physician partners to send patients into our jointly
owned centers, which we otherwise might not have seen. Additionally, our joint venture partners are helpful in providing support if needed
in establishing long-term equitable outpatient reimbursement rates for our services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to make progress with our artificial
intelligence initiatives. Our Enhanced Breast Cancer Diagnostic Program in mammography offering continues its rollout within our East
Coast markets. We are refining the program as we learn from our early rollouts. We are testing different levels of pricing, various service
offerings, new marketing collateral, and local market sales and marketing strategies. While there is much work to be done to optimize
the program, we are experiencing positive results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are identifying cancers that otherwise would
not have been found until at later stages and more advanced stages. Since the inception of the EBCD program, we have diagnosed over 300
breast cancers that without the intervention of artificial intelligence would have gone undetected. Detecting cancer sooner allows for
better patient outcomes through earlier treatment and intervention, and reduces cost to the healthcare delivery system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, we are reducing callback rates for
patients through the use of artificial intelligence by being more definitive with the initial screening exam. This saves time and money
for our patients and their insurance companies and enables our radiologists to be more efficient as well as reducing stress on our patients.
We are currently experiencing approximately 20% adoption rate from our mammography screening patients and believe we will see greater
uptake as we get better at communicating and marketing the benefits to our patients and their referring physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recognition our centers are receiving from
offering this unique program has benefited our local branding and distinguished our quality from our competitive centers who do not offer
similar capabilities. We expect to see an increase in this business throughout the remainder of 2023 and into 2024 and look forward to
providing updates each quarter with our progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consistent with our efforts throughout the pandemic,
we continued to carefully manage our liquidity and financial leverage. Despite having front-loaded capital expenditures in the first quarter,
which included liberal spending to fund our de novo centers in development at first quarter&rsquo;s end excluding the losses in our artificial
intelligence reporting segment, our leverage was 3.4 times net debt to trailing 12 months EBITDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our liquidity also remained strong. We ended the
first quarter with $90.8 million of cash and we were undrawn on our $195 million revolving credit facility. Our day sale outstanding at
March, 2023 was 35.6 days, which we believe to be one of the best in the industry. While we are committed to growing and expanding our
business, we will also continue to follow a methodical and disciplined approach to managing our financial leverage. Our low leverage,
lower cost of capital, and strong liquidity relative to many other industry operators position us to capitalize on acquisition opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the significant rise in interest rates over
the past 12 months, along with the challenging labor market, there are many struggling operators in our industry. Some of these operators
will be unable to compete for acquisitions that may arise, while others may be targets of consolidation themselves. We remain patient
and disciplined in our approach to acquisition, focused first on our core markets where we bring unique synergies and cost savings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we are interested in expanding our geographic
reach with larger platform acquisitions and new geographies, those acquisitions must come with scale, have a path to organic growth and
be actionable without causing our leverage to increase materially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I'd like to turn the call back over
to Mark to discuss some of the highlights of our first quarter 2023 performance. When he is finished, I will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Howard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I'm now going to briefly review our first quarter
2023 performance and attempt to highlight what I believe to be some material items. I will also give some further explanation of certain
items in our financial statements as well as provide some insights into some of the metrics that drove our first quarter performance.
I will also provide an update to our 2023 financial guidance levels, which were released in conjunction with our 2022 year-end results
in March.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In my discussion, I will use the term Adjusted
EBITDA, which is a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and
amortization, and excludes losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments and non-cash
equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling
interests in subsidiaries and is adjusted for non-cash or extraordinary and one-time events taking place during the period. A full quantitative
reconciliation of Adjusted EBITDA to net income or loss attributed to RadNet, Inc. common shareholders is included in our earnings release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that said, I'd now like to review our first
quarter 2023 results. For the first quarter of 2023, RadNet reported revenue from its imaging center reporting segment of $388.4 million
and Adjusted EBITDA, excluding losses from the AI reporting segment of $52.7 million. Revenue increased $47.3 million or 13.9% and Adjusted
EBITDA excluding losses from the AI reporting segment increased $10.9 million or 26.2%. Including our AI reporting segment, revenue of
$2.1 million, revenue was $390.6 million in the first quarter of 2023, an increase of 14.3% from $341.8 million in last year's first quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unadjusted for AI reporting segment Adjusted EBITDA
losses of $4.5 million in the first quarter of 2023 and $3.6 million in the first quarter of 2022, Adjusted EBITDA for the first quarter
of 2023 was $48.2 million as compared with $38.1 million in the first quarter of last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss for the first quarter of 2023 was $21
million as compared with diluted net income of $3 million for the first quarter of &lsquo;22. Net loss per share for the first quarter
of 2023 was negative $0.36 compared with a diluted net income per share of $0.05 in the first quarter of 2022. Based upon a weighted average
number of diluted shares outstanding of 57.7 million shares in 2023 and 56.4 million shares in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were a number of unusual or one-time items
impacting the first quarter, including the following: $4.1 million of non-cash loss from interest rate swaps; $959,000 expense related
to leases for our de novo facilities under construction that have yet to open their operations; $1.6 million of non-cash increase to contingent
consideration related to completed acquisitions; $719,000 expense related to the revaluation of holdbacks related to completed acquisitions,
and $7.6 million of net pre-tax expenses related to our AI division.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusting for the above items, adjusted loss from
imaging center reporting segment was $4.7 million, and diluted adjusted loss per share was negative $0.08 during the first quarter of
&lsquo;23. This compares with adjusted loss from imaging center operations reporting segment of $7.6 million and diluted adjusted loss
per share of negative $0.13 during the first quarter of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also, affecting net income in the first quarter
of 2023 were certain non-cash expenses and unusual items, including the following: $12.2 million of non-cash employee stock compensation
expense resulting from the vesting of certain options and restricted stock; $134,000 of severance paid in connection with headcount reductions
related to cost savings initiatives, and $746,000 of non-cash amortization of deferred financing costs and loan discounts related to financing
fees paid as part of our existing credit facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first quarter of 2023, as compared with
the prior year's first quarter, MRI volume increased 16.7%, CT volume increased 16.8%, and PET/CT volume increased 20.9%. Overall volume,
taking into account routine imaging exams inclusive of X-ray, ultrasound, mammography, and all other exams increased 14% over the prior
year's first quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On a same-center basis, including only those centers
which were part of RadNet for both the first quarters of 2023 and 2022. MRI volume increased 11.9%. CT volume increased 10.6% and PET/CT
volume increased 20.5%. Overall same-center volume, taking into account routine imaging exams inclusive of X-ray, ultrasound, mammography
and other exams increased 9.3% over the prior year same quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the first quarter of 2023, we performed 2,504,635
total procedures. The procedures were consistent with our multi-modality approach, whereby 75.5% of all the work we did by volume was
from routine imaging. Our procedures in the first quarter of 2023 were as follows: 369,556 MRIs as compared with 316,784 MRIs in the first
quarter of 2022; 229,379 CTs as compared with 196,461 CTs in the first quarter of 2022; 14,126 PET/CTs as compared with 11,683 PET/CTs
in the first quarter of &lsquo;22 and 1,891,574 routine imaging exams compared with 1,672,257 of all these exams in the first quarter
of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall GAAP interest expense for the first quarter
of 2023 was $15.7 million. This compares with GAAP interest expense in the first quarter of 2022 of $11.6 million. The higher interest
expense resulted from an almost 500 basis point increase on our unswapped debt exposure as well as the additional debt we have at our
NJIN, New Jersey Imaging Network joint venture from its refinancing transaction last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regards to our balance sheet, as of March
31, 2023, unadjusted for bond and term loan discounts, we had $789.2 million of net debt, which is our total debt at par value less our
cash balance. This compares with $693.8 million of net debt at March 31, 2022. Note that this debt balance includes New Jersey Imaging
Network's debt of $148.1 million for which RadNet is neither a borrower nor guarantor. As of March 31, 2023, we were undrawn on our $195
million revolving line of credit and had a cash balance of $90.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2023, our accounts receivable balance
was $176.4 million, an increase of $10 million from year-end 2022. The increase in accounts receivable is mainly the result of the increase
in our procedural volumes and revenue, particularly during the second half of March, as well as the normal first quarter effect on cash
collections from the resetting of patient deductibles each year in January.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our days sales outstanding or DSO remains near
the lowest levels of our company's history at 35.6 days at March 31, 2023. Through March 31, 2023, we had capital expenditures, net of
proceeds of the sale of imaging equipment of $75.7 million. This total includes $19.8 million spent under capital leases and the remainder
spent in cash. Additionally, the total includes approximately $38 million spent to purchase imaging equipment already in service, which
we were renting on operating leases. Note that each year we front load the majority of our capital decisions into the first part of the
year. CapEx is disproportionately higher in the first half of the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I'd like to update and revise our
2023 financial guidance levels, which we released in conjunction with our fourth quarter and year-end 2022 results. We amend our previously
announced guidance levels as follows: for revenue, we increase both the low end and the top end of our guidance level by $25 million to
$1.550 billion to $1.600 billion; for Adjusted EBITDA, we increase the bottom and the top ends of our previously announced guidance ranges
by $5 million to $225 million to $235 million; for capital expenditures, we're increasing our low end and high-end ranges by $5 million
to $110 million to $120 million for the year; for cash paid for interest, we're increasing the low and high ends of our range by $10 million
to $45 million to $50 million; and for free cash flow generation, we're decreasing our guidance ranges at the low end and the high end
by $5 million to $65 million to $70 million. For our artificial intelligence segment, our guidance levels remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We've increased our guidance ranges for revenue
and Adjusted EBITDA to reflect the first quarter's strong financial results as compared with our original budget. Though we remain vigilant
about the economic environment, supply chain disruptions, inflation, and the possibility of further variants of COVID-19, we have opportunities
to expand our operations in all of our markets, both organically and through new acquisitions and joint ventures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also increasing our guidance levels for
cash interest expense and capital expenditures to account for both the rising cost of interest on that portion of our debt, which is not
subject to our interest rate swaps, and to fund the completion of certain of our de novo facilities scheduled to open during the remainder
of 2023 and the first half of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to Medicare reimbursement for 2023,
there's nothing to report at this time. As is typical each year, we are expecting CMS to release a preliminary rate schedule sometime
in June or July. At which time we will analyze CMS&rsquo;s proposal and our industry&rsquo;s lobbying group, the Association for Quality
Imaging, will provide CMS our industry's feedback.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of our second quarter financial results
call, we will be in a position to comment on CMS's proposal and its impact, if any, upon RadNet&rsquo;s future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I'd now like to turn the call back to Dr. Berger,
who will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we move towards the midpoint of 2023, we are
excited about the initiatives we have for the remainder of the year. The demand for diagnostic imaging is greater than ever. Technology
embedded in state-of-the-art imaging equipment continues to improve. Contrast materials and radioactive pharmaceuticals for PET scanning
are being advanced. Significant progress has been made in post-processing software. These factors and others are driving increased clinical
indications for ordering diagnostic imaging procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, our centers are extremely busy and
we are pursuing expansion opportunities in all of our core markets through a focus on same-center performance, de novo centers, health
system partnerships and tuck-in acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To meet the heavy demand for our services, we
are investing substantial capital to continue construction of de novo facilities in core markets. Our acquisition pipeline remains active
for tuck-in acquisitions in our core markets, and we are in various stages with new potential health system partnerships as well as expanding
existing joint ventures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we are advancing our AI strategy
and now have algorithms to address three of the top four most prevalent cancers. We expect to have tools that lower the cost and increase
the accuracy and early detection of cancer diagnosis in a form that can be created to influence widespread population health initiatives.
While this artificial intelligence can serve to lower our costs of delivering our services, more importantly, artificial intelligence
could create substantial new revenue streams for our company. We have already begun deploying our breast artificial intelligence and anticipate
accelerating its growth for the remainder of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, in addition to this clinically focused
artificial intelligence, we believe artificial intelligence could have a material impact in almost every facet of our business processes
in the areas such as patient scheduling, clinical reporting, medical coding, sales, marketing and workflow improvement with the adoption
of Generative AI through ChatGPT algorithms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conclusion, we are excited and enthusiastic
about the opportunities that lie ahead for RadNet, and we look forward to updating you further in the coming quarters regarding our progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operator, we are now ready for the question-and-answer
portion of the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. (Operator Instructions). Our first
question comes from Brian Tanquilut with Jefferies. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey, good morning, guys. Congrats on a really,
really solid quarter. I guess, Mark, I'll start or maybe for Howard too, volumes are obviously strong. I see the strength also specifically
in advanced imaging. Is this the proof that side of service shift is really accelerating now? I know, Howard, you said that this is something
that you expect will continue. Maybe without going to like a long-term guidance situation, any color, any way you want us to be thinking
about kind of like how we should be modeling organic growth maybe on a two-to-three-year horizon? Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, Brian. Thank you. Yes, I think that
part of the significant increase that we had in our first quarter volume, while it's due to many factors, given the conversations that
we're having with payors, we see a definite and more active effort on the part of virtually every commercial payor trying to shift business
away from hospitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I might add that I don't think this is just an
issue about reimbursement differences. I think it's also the preference of patients who prefer the more stable and less complicated environment
of outpatient imaging centers to enhance a patient experience. I think patients are becoming more aware of the difference both in the
quality of service as well as the cost, which is being made abundantly clear by the commercial payors. I think what portion of increases
from that, I don't know. I think this is a slow process because it still requires interaction with the referring physicians who by and
large control for the most part, where patients are directed for their outpatient imaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">But clearly, these efforts on the part of commercial
payors through plan design initiatives, which we're seeing more and more to encourage the patients into outpatient centers is being accelerated.
I expect this process to continue for quite some time, both because it'll be a slow process, as one that is almost inexorable. I think
the continued growth of our joint venture strategy with our hospital systems is indicative of the fact that they recognize that this is
an inevitable change, and by partnering with RadNet, they provide themselves an outpatient strategy to at least benefit from that transition
of those services, as well as bringing them into an environment, which has better cost controls on managing these patients rather than
in hospital settings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would just add to that, Brian, that it's not
only just the payors&mdash;the differential in pricing and the plan design that the payors are instituting that might have different copays
for hospital-based imaging versus freestanding outpatient imaging. But they're also doing it through preauthorization processes where
today, most utilization is managed either internally with preauthorization processes at the payors or through third-party services such
as radiology benefit managers. Once the preauthorization occurs, they are directing the patients to the lower cost sites of care, meaning
the freestanding centers and the patients also&mdash;we've heard a lot of anecdotal stories from patients about how appreciative they
are in coming into the outpatient settings because many of them&mdash;and more and more over the last five, 10 years, many more patients
have elected to go into higher deductible programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the patients themselves are shouldering more
of the burden of their healthcare costs, they really experience the benefit of coming into outpatient freestanding settings where the
cost could be anywhere between half the price and a quarter of the price. The patients are over time&mdash;and this is part of the slow
process that Dr. Berger just mentioned&mdash;the patients are getting educated over time as to the differential in the pricing discrepancy
just as much as the payors have been become educated on that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Got it. Then maybe shifting to AI, obviously,
a key emerging part of your story. Maybe Howard, if you can give us some color or updates on where things stand. I know you've had some
announcements and some FDA approvals recently. But also, in your prepared remarks, you touched on business processes, and that's kind
of new to me. Any color or any updates you can share would be great? Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, good question, Brian. I think I'll touch
on it somewhat in this close call&mdash;earnings call. But we'll have more to say about it in the very near future. But it's clear that
artificial intelligence is on everybody's lips and minds these days. I think despite the fact that maybe there are some aspects about
artificial intelligence that people are concerned and leery about inside healthcare and particularly in the imaging space, I see it as
an evolutionary development in the delivery of radiology and imaging services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Really it falls into two different categories
that we&rsquo;re broaching. One which we've already made substantial progress in, and that is clinical applications, particularly in the
field of cancer screening with breast, lung, and prostate for which we believe much like mammography, there will be screening tools for
these three cancers that will be used far more regularly in the future as we and others roll out opportunities for both men and women
to get these tests and diagnose cancer at an earlier stage, which ultimately leads to a better outcome for the patients as well as the
healthcare system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we noted recently, we had another FDA approval
in our prostate screening tool to their 3.0 level software. The significance of that is that it's now ready for a better adoption by our
radiologists to improve their accuracy and workflow. We are working aggressively on that inside of RadNet where we do more prostate MRI
scanning than any other organization in the country, and which as we showed you in our results are MRI and PET/CT volume have increased
dramatically primarily as a result of the increased prostate screening and detection tools.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">But in addition to that, this lays the framework
for us to advance the prostate tool much as we have with breast and which we are doing with lung into a screening tool for men and women
who want to come in and test for early high-risk patients for both prostate and lung cancer. I think you can&mdash;and we'll see a lot
more from that, both in terms of the development as well as the adoption of these tools as they roll out to our patients in our regions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">But the other side, which we now are getting equally
excited about is really generative artificial intelligence. It appears to us that there isn't anything that we do on the operational side
that couldn't be improved with the adoption of Generative AI and otherwise known as&mdash;for this discussion at least as ChatGPT&mdash;whether
it is scheduling of patients or reporting tools, coding, workflow, sales and marketing, every part of what we do could be improved by
artificial intelligence. I think as we'll be talking about in the later part of the second quarter here, we will be positioning ourselves
to take advantage of what we've been doing for the last 15 years in developing our own internal information systems and expanding those
onto new platforms that not only are far more efficient in their use, but then will be adopting some of these new tools to improve our
workflows and processes, which in and of itself will help us address some of the workflow as well as labor shortages that we have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is a big focus of the Company, which, as
I mentioned, we hope they have more information about later in the quarter, and one that is very exciting, not only for us, but what it
could represent for the entirety of the radiology and imaging community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. On that front, Brian, we just got some very
good news this morning that the U.S. Preventive Services Task Force, which advises CMS and other payors are now recommending that mammography
should start at the age of 40. They had come out with a pretty controversial decision in 2009 to recommend that women over the age of
50 should start getting mammography exams.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is a big deal because we think that&mdash;well,
what they're saying is that this could lower the mortality for breast cancer by over 20% by recommending that women age 40 and over get
their annual screenings. I think it's going to obviously be very positive for our business and for the industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awesome. Thanks, guys, and congrats again.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next question comes from John Ransom with Raymond
James. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey, good morning. I just wanted to probe a little
bit on your guidance for the rest of the year. It seemed like you didn't really raise your EBITDA outlook for the next three quarters.
Should we think about that as conservatism? Or is there something factoring into the algorithm that we haven't thought about in our model?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think it's conservative, John. We are very pleased
with our first quarter results. Part of those results were helped by less weather-related issues in the Northeast and mid-Atlantic that
we generally experience. I think before we become more aggressive, we want to see what the second quarter looks like, which is one that
is generally not challenged by weather conditions. We felt prudent to show upward direction, both on the revenue side and on the EBITDA
side and feel that if we can continue the trends that we've seen here in the first quarter, I believe we can look forward to continuing
to increase our guidance at the end of this second quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I'll add, we are seeing the same strength in April
that we experienced in the first quarter. We're pretty optimistic and upbeat.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great. The second question I have is just trying
to find a correlation&mdash;maybe it does or doesn't exist. I know most of what you do is diagnostic, but it's hard not to notice that
your jump in revenue starting in the fourth quarter and continuing, also, correlated with the big upsurge in first quarter across the
board with surgeries, particularly orthopedic surgeries. Is there a line we can draw all the parts of tailwinds and volume? Do you think
the uptick in people just getting screened for orthopedic and other surgeries is also helping your volume story?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, I think if anything, John, that may be more
a reflection of post-COVID return to normal. As you're probably aware, elective surgeries were put off throughout the past three years
and many people delayed getting elective surgeries, particularly orthopedic surgeries, which generally tend not to be as urgent as some
others. I think now that people are returning back to more normal physician visitation, more active, whether it&rsquo;s through sports
or other activities that got somewhat curtailed, I think we're seeing the after effects of that. We would expect that volume to continue
to increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I might say that there is more and more reliance
on, particularly for sports injuries and orthopedic issues, more and more reliance on MRI scanning. As the quality of the MRI scans improve,
as well as the scanning time shortened for better patient experience, we're finding more and more people are willing to undergo these
procedures which have become very small in the total cost of care for orthopedic conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Just a ballpark. I mean, for every 100 scans that
you do across all your modalities, approximately what percent of those would you say are kind of pre-surgical scans versus just routine
or ongoing diagnostic scans like the breast cancer scans?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, in the case&mdash;if you're talking about
advanced imaging and in particular MRI scanning, I would say that the preponderance of what we do are neurologic and musculoskeletal applications.
Probably, I'm going to say about 80% of what we do falls into one of those two categories. The rest of the MRI scanning, which comprises
maybe perhaps 20% is for the rest of the body. Of that 80% that is either neurological or musculoskeletal related, I'm going to guess
that it's probably two-thirds musculoskeletal and one-third neuro application. It is a huge part of the industry in terms of its overall
value in the treatment of musculoskeletal problems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. I'm probably looking for a problem that
doesn't exist, but has this uptick in utilization pressured any of your capitation economics in California?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No. Our capitation contracts are something we
negotiate regularly and are a reflection of utilization. Capitation is really as much as anything else, a form of payment that makes it
easier, both for our contracted parties and ourselves to reduce billing costs and whatnot. But as utilization increases, that cost eventually
gets passed on to our capitation party. It may lag a little behind, and I think there's more&mdash;we're more aggressive about it now
than we used to be and we're having very good success in those conversations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A couple more kind of model stuff. Exactly as
we think, let's just pick fourth quarter, for example. How should we think about the core labor inflation once you sort of have lapsed
your catch-up payments for lack of a better word? How are you thinking about your core labor inflation once we get through the full reset?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, we've built into our modeling, John, an
increased cost of our labor expense as it relates to our employees, both physician and non-physician. What we're hoping for is, even though
we've built in the continued cost of using temporary agencies and some overtime, we hope that the improved labor conditions that will
allow us to fill open positions will&mdash;and even if those come at higher costs, which we believe they will, we will have some offset
of that to the lowering our costs and dependence on overtime and temporary agencies. We've built that in and in our first quarter model,
we were pretty accurate with our prediction of our employee expense costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. We&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I guess what I'm getting at, should we think about
like maybe a mid-single digit kind of underlying core inflation rate asking all the puts and takes with temp staffing? Or we're just looking
for a number there?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would&mdash;as it relates to employees and salaries,
John? Is that what you mean?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think that's reasonable. But again, we
very much hope because we've built into our model continued use of temporary agencies. We hope that is somewhat offset, but I think that
kind of increase is certainly reasonable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I know there's probably not one answer here, but
let's say we again look same-store&mdash;if you were to do say, 5% to 7% growth in underlying volume, what's the variable cost associated?
I know it's probably a stair step and depends on the capacity of the individual center, but we're just trying to think about the operating
leverage fixed versus variable. Because you really haven't operated at this level of volume growth before. I don't know that we have a
real roadmap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. It's a good question and one that we continue
to wrestle with all the time because of increased costs that were experienced that we did in the past. What I would point you towards,
which we're very pleased with, is the significant improvement in our margin in the first quarter where we went from 12.2% to 13.6% in
our EBITDA margin. We do have significantly higher costs in our first quarter, as most companies do related to employee expenses and from
withholding and other benefits as well as most of our bonuses for the year are expensed in our first quarter. That number will go down.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We're confident that we can continue to improve
our margins. But I will tell you that I believe part of the improvement in margins we're hoping can come from increasing in our reimbursement
rates, which we're actively pursuing in every market that we're in. I think some of these increased costs are just a fact of life for
every business today. But I think we have tools to offset that and I'll harken back to the comments I made about artificial intelligence,
which I think can have both improvement in our efficiencies with our radiologists and our patient throughput as well as attacking and
approaching virtually every aspect of our business through algorithms related to Generative AI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great. Thanks so much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, John.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, John.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next question comes from Larry Solow with CJS
Securities. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great. Thanks. Good morning, and congrats on a
good start to the year. Just a few follow-ups, I guess on the margin question for starters. How much does mix&mdash;and I realize it's
probably a slow improvement, but obviously mix and turn to much higher margin advanced imaging including rapid growth and PET/CT in the
last couple quarters&mdash;how much does that play into margin? Maybe over time&mdash;I know it's been pretty slow improvement over the
last few years, but could that potentially pick up as especially like this PET/CT, which is growing really rapidly continues to drive
more of your revenue contributions?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi Larry, and welcome to the family.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very appreciate it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think we have to look at this in a couple of
different ways. When we talk about mix, there's two&mdash;and I think you're talking about modality mix...</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Versus payor mix, right?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Because payor mix has remained pretty stable
for a long time with us. I think you're right that the modality mix is shifting. But even if there's an increase in some of these exams
like the PET/CT huge increase that we saw particularly related to prostate screening and scanning, it still represents a relatively small
percentage of our total volume. I think, Mark, correct me if I'm wrong, it's maybe...</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It's under 1%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under 1%...</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representing about 5% to 6% of our revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. That will also be a slow adoption. The margins
on that are higher to be sure, but we see opportunities there, not just from what we're doing today, but what we expect to do tomorrow.
We're hopeful that the Alzheimer's adoption, which we believe is a great tool, not necessarily for just diagnosing Alzheimer's, but monitoring
the treatment of the new drugs, which all seem to have potential neurologic and primarily brain impact, but we see those as increasing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To that end, we have upgraded a substantial number
and will continue to upgrade a substantial number of our PET/CT scanners, both to improve the quality, but more importantly and much like
we're seeing with CT and MRI, the new equipment and new software that can be adapted to these has had a substantial improvement in scanning
time. What we may wind up seeing is that the shift is not so much because we're getting a lot more demand, but we're able to access our
backlogs by improving our throughput on our equipment with the investment that&mdash;the capital investment we're making in hardware and
software to shorten scan times and to improve the image quality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both of those in and of itself could have a significant
impact on our margins, given the fact that the relative cost of our overhead remains pretty flat as we can improve our patient throughput.
I think it's a very dynamic issue that we'll continue to monitor and given some early results of how effective it has been to reduce the
scan time, particularly with MRI, we have accelerated some of the software, which are relatively nominal costs to us, relative to the
total cost of an MRI system for greater adoption in the second half of this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Got it. Appreciate all that color. Then just a
second question, just a follow-up on the Enhanced Breast Cancer Detection. You mentioned you're refining that program a little bit, some
new pricing. Can you just give us a little&mdash;an update on where you stand there? I think if I'm not mistaken, I believe you guys are
charging $50 to $60 per patient there. Can you also just&mdash;I think you mentioned 20% sort of penetration at the centers you're now
offering this at. Can you sort of just update where we stand there? Is it just on the East Coast today and when do you expect to have
it across your centers?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. Thanks for the question, Larry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have intentionally delayed rollout to really
get a sense of what we need to do to make this new technology and this clinical tool, if you will. I want to emphasize that it's a clinical
tool and not just an artificial intelligence tool because it involves utilizing our radiologists to look at the results of artificial
intelligence and compare it with their initial reading and make certain that everybody gets a sense of what the most accurate diagnosis
at that moment and time should be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, we're finding that by looking at
focus groups, looking at various comments back from the patients that we see, that this is not something that everybody is just going
to come in and adopt, given that there's an educational process to this that we have found both for the patients as well as their referring
physicians. We've intentionally delayed the rollout. We might be a little bit behind that. We currently have it rolled out in about 80%
of our markets on the East Coast. Two of our biggest opportunities we've&mdash;for the rollout on the East Coast, we've delayed based
on some initial feedback here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We think that the price point on this is somewhere
between $60 and $75 that patients who enroll in it are very comfortable with. Actually, some are surprised that we're not charging more.
I think part of what we're also doing is trying to provide other tools in this early Breast Cancer Detection that will further enhance
the risk assessment that patients have for getting cancer well before it may even be diagnosed by artificial intelligence. We're excited
about this, the announcement today that the U.S. Public Service Task Force has finally lowered the recommendation for when women begin
getting their screening mamos from 50 to 40.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The importance of that is that that's what a lot
of the commercial payors have adopted. They're clearly going to change and now put an emphasis on this. There's 20 million women between
that age group that now should be getting their mammography&mdash;some of which already have. I don't want to say that it's been that
black and white. But clearly, now as it gets adopted into the health plans and preventative health for our patients, we expect that an
increase, a substantial increase in our mammography screening business and therefore greater adoption of artificial intelligence and clinical
tools for assessing early Breast Cancer Detection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I can't emphasize enough of how valuable and how
important that is and I'll emphasize something that we've talked about. When breast cancer is diagnosed in the earliest stages, however,
you want to find it, Stage 0 or Stage 1, there's a 99% five-year survival rate. Effectively, if everybody that should be getting mammography
screening was getting it, nobody would die from breast cancer because it's not a fatal disease, if it's caught early. It's one of those
things that modern medicine with its diagnostic tools is whether its treatment tools has had an enormous impact and should have an even
greater one going into the future with the adoption of artificial intelligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We think we're on the cusp of something that not
only will be, I think, very transformative for breast cancer, but also for prostate and lung cancer. It's getting everybody on board with
the value that these tools can provide that ultimately will lead to a better outcome for all the stakeholders in the healthcare system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Got it. Great. I appreciate that. Then just lastly
on the&mdash;just on de novos. Can you just clarify? I think you had 15 de novos, I think, lined up, right? Two I think opened last late
in &rsquo;22 and then you have still the six and then of the remaining 13, six respect to open, I guess more like back half of this year,
early next year, and then the remaining seven in &lsquo;24. Is that right?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. That's right, Larry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Feels like I thought it was a little bit&mdash;I
thought some expect to open up a little bit earlier this year. Regardless, I guess your guidance hasn't changed. This is probably not
a bad thing. But is it a little bit slower the ramp of these or maybe I was just missing something?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. Everything has become more complicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A little slower. Sure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Post-COVID, most of the building departments in
virtually every market that we're in have reduced staff or are slower to turn around permits, slower to get inspections. Unfortunately,
some of the projects have been delayed. But that won't deter us. We're actually looking beyond 2024 at other de novos that we're going
to start talking about and become actionable primarily because this is taking us longer than we anticipated and the need for greater capacity
to scan not only the cases that are being asked of us today, but as we increase screening for various cancers and increase the amount
of business there, we don't want to let what should be a fundamental shift in the treatment&mdash;diagnosis and ultimately treatment of
cancer be delayed because there isn't enough capacity of equipment and personnel. These are things that we're actively looking at every
day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Got it. Great. I appreciate all that. Thanks so
much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Larry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This concludes our question-and-answer session.
I would like to turn the conference back over to Dr. Howard Berger for any closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Again, I would like to take the opportunity to
thank all of our shareholders for their continued support, and the employees of RadNet for their dedication and hard work. Management
will continue to do its endeavor to be a market leader that provides great services with an appropriate return on investment for all stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We eagerly look forward to our next call where
we believe we'll have more information about the continued success and growth of the Company as it exists now, as well as other opportunities
to have a substantial impact, not only in radiology, but in healthcare. Wishing you all a good day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The conference has now concluded. Thank you for
attending today's presentation. You may now disconnect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rdnt-20230509.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOa2G2aPty552uYkxvmR1fZmKLyQkH/IgyCLjlOd2IbQE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:RDNT="http://radnet.com/20230509" elementFormDefault="qualified" targetNamespace="http://radnet.com/20230509">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://radnet.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20230509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20230509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rdnt-20230509_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rdnt-20230509_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://radnet.com/role/Cover" xlink:href="rdnt-20230509.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://radnet.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #B @\# 2(  A$! Q$!_\0
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M/!7@I/ NG?88;R]NK&,@6Z7,AEDMU'1 Y^9@. -V6XY)ZUOT %%%% !1110
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MZ+ZG^M>N_#OX,Q^+-3^U7BG[#"V2,?ZT^G^)KVN&.'3+)458X88$& /E5 *
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M<\-:M9ZQI=XH:*>VD#J?8^A]0:\A^//_  2\^!W[0ADFUCP#HMGJDF2NH:9
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M8/\ A]I_B;QY>7-GIVIWRZ=;B"$S2/*4=\8';:C<U\TK_P ''_[.)_YBFO\
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M&\2VCJI^5[Z4*\Q/;*J43V*M7T[_ ,$H/@&OBBZ;7[Z'=I^CX"!AQ+,>0/\
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MG_!)<;O^"C_P9!Z?\)79?^C!7@?B7_D/WG_7>3_T(U[Y_P $E_\ E)!\&?\
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M#1#IR.V/2NH\&>-])^(?AVVU;0]2LM6TV[4-%=6LHEBD'L10!L4444 %%%%
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M'_HA:M?"S.3?,EZGHG_!8/\ :)\:_!'XB^#[7PKXBU#18+[3II)TMWVK*RR
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M?PQ>:1I64ZI$"QZ*NJ7:J/P4 ?A7SC_P6J^*5QXI_:4T_P -+)_H/AG38V*
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M;KA?K7V-_P %^/\ E*E\2/\ =T__ -(8*^.;/_CY3ZU^4Q_Y'"_Q_JC^S/\
MFAO^Y?\ ]L1^F'_!>S]G'^S/@G^SO\5+.W_=ZKX0T_0-1D Z/':)+ 3[LIE'
MT45^9L3[&#5_1=^WM^S=_P -,_\ !$JTTV"W\[5M#\%Z7K^G;4W-YMK:Q2E5
M_P!IHQ(G_ Z_G/!YKJXFHRP^/]O#K9KU1XOA+F$,TX=E@:^OL[P:_NM77YV^
M1_1__P &_?[3'_#0/_!/C0].NKCSM7\ SMH%R"<MY2?/;M]/*95!_P"F9K[C
M'6OP-_X-E_VFO^%9?M<ZO\/[RY$>G_$+3L6Z$\&]MMTD>/3=$TP]\+7[Y U^
MB87$*O1C675)G\PYWELLOQ]7!3WA)KY='\T<Y\6?'-O\-?AAXB\0WC!+30]-
MN+^9L]$BB9S^BU_(IXV\5W'CKQIJVN7C;[S6;V:]G8_Q/)(SL?S:OZ5/^"X_
MQ@'P:_X)H?$BXCF,-WKMDFAVV.K&YD6-Q_W[,GY5_,N1S7PO&6(YJL**Z)O[
MS^@_ K >SP>)QTOM227I%7?Y_@>]?\$Z_P!M0_L#_M&6OQ"CT"'Q'<V5C<6D
M-O+*8U1IEV%\^R[A^-?H ?\ @ZPUG/\ R2W3O_ YZ^3?^">G_!&/QQ_P4.^%
M.J>+]!U[1]#T[3=2.EXO8W9II$C21B,=@)%%>^_\0LWQ2/\ S/GA7_P&D_QK
M/#_VY3IJ%-/E2LMCMS.7A]BL5/$8N:=23;EJ]]CX&_;#_:#C_:G_ &D_%GQ"
MCTB+0F\578O7LHW\Q8G\M0Y!]W4M^-;7_!/;XQ-\!OVU?AGXJ\[[/#I/B&T:
MY?TMWD$<WYQLX_&NV_X*/?\ !+_Q9_P3;U'PO#XDUC3=:C\51W#V\ME&R+&8
M2@93N/7]XOZU\UZ9<M:WD<B-M96R".Q!R*X,MJ5L/F<'77O.5G\SZ;B3#X+-
M.$:L,N:E34/<_P"W.WGH?V,12B959>5QP?6H=9/_ !*[C_KDW\J\W_8J^+*_
M'3]DOX=>+1(LDFO:!9W$[ _\M3$HD_)PP_"O2-:_Y!EQ_P!<F_E7ZG+8_CFC
M\:]3^//Q+_R'[S_KO)_Z$:]\_P""2_\ RD@^#/\ V-=E_P"ABO _$G_(>O?^
MN[_^A&O?/^"2P_XV0_!G_L:[+_T.OS'AW_D9KUD?V!XG?\DE4](_FC^I9#_*
MOS]_X.4?B4O@K_@F]>:7D>9XJUVQT]1GLC-<-_Z( _&OT =L*.:_"W_@YZ_:
MQM?B-\<?"WPMTF[6XM_!<4FH:KY;Y5;R< (C=MR1C/MYN.M?;9[B%1P4F^JM
M]Y_.OAME4\=Q!AXQ6D7S/R4=?SL?EHGWJ_67_@U3^'WV[XZ?$[Q,T)*Z7H5M
MI\<F.C3SER,^X@'Z5^32_,WK7] W_!M!\ YOAE^PYJ/BN[A,=UX\UI[F$E<%
MK6W40QD>Q<2FOF^#,.W4G6Z))?-GZ]X[9@HX/#8);N3E\DK?J?HWG*5^"O[1
MO_)P'C?_ +#M[_Z/>OWJ(PE?@K^T;_R<!XW_ .P[>_\ H]Z^^/YG+'_!-[_E
M,#\'_P#KPU/_ -(KFOW(\>>#;/XA^"]4T+4(_-L=6M9+2=2/O(Z%3^AX]Z_#
M?_@F]_RF!^#_ /UX:G_Z17-?O!'T_"JET]#*'Q,_ 'XL?#R[^%_Q%U[PQJ4?
M^DZ+>2V4H(^_L8KN^C#!^E<[96B:?:10Q_+'"@C0>@4 "OM/_@M)\#_^$(^/
M&F>,;6';9^+K4+.RCY1<PX4Y]VC,?X@U\85)J=-^P/\ \I@_@3_O7_\ Z175
M?ONW]*_ C]@?_E,'\"?]Z_\ _2*ZK]]V_I5U.AG3Z^I\'?\ !=O_ ))OX!_[
M"EQ_Z*6OS1E_U9K]+O\ @NW_ ,DW\ _]A2X_]%+7YHR_ZLU$=S0_07_@V<_Y
M,O\ &W_8\7G_ *3VU?H[7YQ_\&S8S^Q?XV_['B\_])[:OT<JJGQ&='X$%%&:
M,U)H%?C'_P %3O\ D^CQM_OVW_I+%7[.5^,?_!4[_D^CQM_OVW_I+%0!\??M
M._\ )%]4_P!Z'_T:E?T.?LH_\FQ?#O\ [%K3O_26.OYX_P!IW_DB^J?[T/\
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M\ZCS(V]"5/S*17M6: ,W0->35[90W[NZ11YL).&0UI9K@OC3\.-2\3:3]O\
M#MXVF^(;,;K>53A9?]A_4&OGK0_^"HEE\)O&#>%_BYI-UX;U&!MC7Z1$PMC^
M-EZX/JN10!]A9I'^X?I7-?#7XO>&?B_H*ZEX9U[2M<LW /FV=PL@3/9@"2I]
MC@UTCM\K?2@#^:7_ (+[<?\ !5#XD9_NZ?\ ^D,%?'EI_P ?4?UK],/^"S'_
M  3F^-GQY_X*)^.O%/A'X>:YKF@ZFME]GO+?R_+FV6<2-C+ \,I'2OF33/\
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MZC@=Q7[*L/Y5=3H9T^OJ?!O_  7;/_%M_ /_ &$[C_T4M?FC)]PU^K'_  6
M^!/B[XY>!_!EMX3T.\UJXT_4)YKA8,9C5HU4$Y([U\&_\.^?C-_T(.L?^0__
M (JH-#H/^"8_[<<7_!/;X+:YX3FT*3Q$^L:[-K(N$G\CR_,CC39C!Z>7USWK
MZ3_X?M6W_0@S?^!X_P#B:^3?^'?'QF_Z$/6/_'/\:3_AWS\9O^A!UC_R'_\
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M10 ;?:F^6OI3J* &K$%%.(R*** &^4*/*%.HH ;Y0H5-M.HH **** "BBB@
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M4+75M%UBUCO+*\MI!)#=0NH975@>00: -JBBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &/ B,# 2(  A$! Q$!_\0
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M/^%?Z?\ \]KG_OI?_B:/92#ZS3.J_P"%V:-_SYWW_?"?_%4?\+LT;_GSOO\
MOA/_ (JN4_X0'3_^>US_ -]+_P#$TW_A [#_ )[7/_?2_P#Q-'LI!]9IG6_\
M+LT;_GSOO^^$_P#BJ/\ A=FC?\^=]_WPG_Q5<E_P@=A_SVN?^^E_^)IO_""V
M'_/:Y_[Z7_XFCV,A?6J9U_\ PNS1O^?.^_[X3_XJC_A=FC?\^=]_WPG_ ,57
M(?\ ""V'_/:Y_P"^E_\ B:3_ (06P_Y[7'_?2_\ Q-'L9!]:IG8?\+LT;_GS
MOO\ OA/_ (JC_A=FC?\ /G??]\)_\57'_P#"#6'_ #VN/^^E_P#B:;_P@]C_
M ,];C_OI?_B:?L9B^M4CLO\ A=FC?\^=]_WPG_Q5'_"[-&_Y\[[_ +X3_P"*
MKC/^$)L?^>MQ_P!]+_\ $TG_  A-C_SUN/\ OI?_ (FCV,P^MTCM/^%V:-_S
MYWW_ 'PG_P 51_PNS1O^?.^_[X3_ .*KBO\ A"[+_GK<?]]+_P#$T?\ "%V7
M_/6X_P"^E_\ B:/8S%]<I':_\+LT;_GSOO\ OA/_ (JC_A=FC?\ /G??]\)_
M\57$?\(99?\ /6X_[Z7_  H_X0VR_P">L_\ WTO^%/V$P^N4CM_^%V:-_P ^
M=]_WPG_Q5'_"[-&_Y\[[_OA/_BJX8^#[/_GK/_WTO^%-_P"$0L_^>L__ 'TO
M^%'L)B^N4CN_^%V:-_SYWW_?"?\ Q5'_  NS1O\ GSOO^^$_^*K@_P#A$;/_
M )Z3_P#?0_PI/^$2M/\ GI-_WT/\*/J\P^NTCO?^%V:-_P ^=]_WPG_Q5'_"
M[-&_Y\[[_OA/_BJX'_A$[3_GI-_WT/\ "D_X16T_YZ3?]]#_  H^KS%]=HG?
M_P#"[-&_Y\[[_OA/_BJ/^%V:-_SYWW_?"?\ Q5>?'PM:_P#/2;_OH?X4G_",
M6O\ STF_,?X4_J\Q?7J)Z%_PNS1O^?.^_P"^$_\ BJ/^%V:-_P ^=]_WPG_Q
M5>>'PS;?\])OS'^%-_X1JV_YZ3?F/\*/J\P^O43T7_A=FC?\^=]_WPG_ ,51
M_P +LT;_ )\[[_OA/_BJ\Y/ARW_OR_F/\*;_ ,([;_WY?S'^%/ZO4%]?HGI'
M_"[-&_Y\[[_OA/\ XJC_ (79HW_/G??]\)_\57FW_"/V_P#?E_,?X4W^P;?^
M_)^8_P */JU0/[0H>9Z7_P +LT;_ )\[[_OA/_BJ/^%V:-_SYWW_ 'PG_P 5
M7F9T&#^_)^8_PIIT.#^_)^8_PI_5J@O[0H>9Z=_PNS1O^?.^_P"^$_\ BJ/^
M%V:-_P ^=]_WPG_Q5>7_ -BP_P!Z3\Q_A2?V/#_>D_,?X4?5:@O[1H=W]QZC
M_P +LT;_ )\[[_OA/_BJ/^%V:-_SYWW_ 'PG_P 57EO]CQ?WG_,?X4TZ3%_>
M?\Q_A1]5J"_M&AW?W'JG_"[-&_Y\[[_OA/\ XJC_ (79HW_/G??]\)_\57E/
M]F1_WG_,?X4W^S8_[S?F/\*?U6H']I8?N_N/6/\ A=FC?\^=]_WPG_Q5'_"[
M-&_Y\[[_ +X3_P"*KR8Z?'ZM^8IOV%/5J/JE47]IX?N_N/6_^%V:-_SYWW_?
M"?\ Q5'_  NS1O\ GSOO^^$_^*KR(V:CNU-^RKZM3^J51?VIA^[^X]?_ .%V
M:-_SYWW_ 'PG_P 51_PNS1O^?.^_[X3_ .*KQXVR^IIIA ]:/J=47]J8;N_N
M/8_^%V:-_P ^=]_WPG_Q5'_"[-&_Y\[[_OA/_BJ\:\L4A2G]3JB_M7#=W]Q[
M-_PNS1O^?.^_[X3_ .*KNM/O$U&QMKN,,L<\:RJ&Z@, 1GWYKY=*^E>B>%?B
MEJS7FC:1]GL_LQDAM=VQ]^S(7.=V,X]J3P=5*XXYKAI-)-_<>S4445Q'KGD_
MQS_UFB_2;_V2E\$_\BQ9?\#_ /0VI/CG_K-%^DW_ +)2^"?^18LO^!_^AM6U
M+XCEQ'P(W****ZCS@HHHH *0K2T4 ,HIV*2@D2D(I:*!C:*4K24""D(I:* &
M44ZD(J@$I"M+1038;24^FXH$-*TA%.HI@1D4W%28II6@D924^FE:8AI6FT^C
M%,DB9::14M-*T"(Z;BI"M-IDC*0BGE:2F*Q'BFLM2E:;3)(BM-Q4I6F%:=Q6
M(R*:5J0K251-B(BFE:E*TTK020D4A%2D4PK5$D9%,9:EII%,FQ"5II%3%:85
MIW)L1;::5J4BFE:9)"RTPBIR*:RU1) 5II%2LM,(ID$3+3&6IB*:5IDV("M-
M*YJ9EIA6J(L0%:8RU8(IC+3(:*Y%-9:G*U&5ID6(&6F%:L%:8RU1#17*UI^%
M%_XJK1O^OV'_ -&+5!EK2\*C_BJ-'_Z_(?\ T,4I?"RZ:_>1]4?2-%%%?+'Z
M0>3_ !S_ -9HOTF_]DI?!/\ R+-G_P #_P#0VI/CG_K-%^DW_LE)X*_Y%FS_
M .!_^AM6U+XCEQ/P+U-ZBD#4M=1YP4444 %%%% !1110 TK24^D(H%8;12TE
M #<44ZD*T )1110(:5I*?28IW ;1113$(5IM/HQ2)&4A6G4E4 PBFU+C--(H
M$1E:;4A6DIDC*0K3L8I*8AF*:RU(5I*"2+%)BI"M-*TQ$=)3Z0K3)&8II6I*
M:5IB(BM-*U-366@FQ#2%:D(II%421E::14M-(IDD++3<5*12%:=Q6(2M-(J4
MK3<4R2%EII6IB*:RTR;$--Q4K+3"*HDC*U&RU,5I"*=R+%<BFD5.RU&5IDV(
MBM,9:F*TTBJ)(&6F$58*U&RTR+$++3&6IBM-(ID6(&6F%:G9:8RU1%B!EK1\
M++CQ1H__ %^0_P#H8JD5K1\+K_Q4VD?]?D/_ *&*4OA95-?O(^J/HFBBBOF#
M]%/)_CG_ *S1?I-_[)2>"_\ D6;/_@?_ *&U+\<_]9HOTF_]DIO@L_\ %,V?
M_ __ $-JVI?$<N)^!>IN4H-)174>8/HIM*#04+1110 4444 %%%% !32*=10
M RBG%:;02!%-IU% ]QM%*124""FE:=10 RBG$4VJ$%-*TZBD(913B*2F(:5I
MI%/I"M,1'2%:D(II% B.BG8I*9(S&*0BGTA6F(B*TE24A6@DC(IM/(I*8AA%
M-IY%)5$V&%:85J4BFXS0(B*TVI66FE:=R2,K3"M2XII%4218IK+4I6FD4$D5
M-*U*5IA%4(C*TPK4Q%-(IDV("M-(J9EIA6F18B(IK+4I%-*TR2%EIA%3E:8R
MU1-B$BFE:E*TW;3)L0LM1E:L$4QEJB;$!%,9:G9:85ID-$#+6AX97_BIM(_Z
M_(?_ $,54*YJ_P"&5_XJ32?^ON'_ -#%*7PL=-?O(^J/H*BBBOFC]!/)_CG_
M *S1?I-_[)3/!?\ R+5G_P #_P#0VI_QS_UFB_2;_P!DIG@O_D6K/_@?_H;5
MM2^(Y,3\"]3;!IU-HKJ/-'44 T4#'!J6F4N: N.HHS10,**** "BBB@ I,9I
M:* &TE/II6@5A*0BEHH ;13J:10(*2EHH ;BDI]-*U5P$HHHH)L-(I*?2%:!
M#::13J*8#"M-J0K32*!$9%)3Z0K3)&D4VG44R2,K32M2D4W% B*D*U(5IN*9
M(RD*T_%-IBL,II6I*3%,DA*TTK4Q6F%:8K$=-*U(5IM,DC*TTBI2M-*TR2$K
M3:F(IC+3N21$4TK4N*:5IB(2M-*U,13&6JN18B*TTBI2M-(IDD3+4;+4^*:5
MIW)("*814S+3"*HFQ$5IC+4Q6FE:9-B K6AX;'_%2:5_U]Q?^ABJ;+5_PVN/
M$>E?]?<7_H8I2^%CIKWX^I[W1117SA]Z>3_'/_6:+])O_9*9X+_Y%NS_ .!_
M^AM3_CG_ *S1?I-_[)47@W_D6[/_ ('_ .AM6]'XCDQ/P+U-VBFAJ=72>:%*
M&I** '44W-.S0/<*<&IM% A]%-!IU!04444 %%%% !1110 A6DIU% AE%+BD
MH$(5I*=1B@8VBBB@0F,TVGT4P&44I6DIB#%-IU%+8D91BE*TE,!N*:5J2D*T
MQ$=-Q4A%-H$,I"M/*TVJ)&TTK4E-Q0(C*TVI2*85H)&%:2GTA%,1&5I*?28J
MB2-EIA6I:0K0(A(I*D*TTK57)(R*814M(5IDD16F%:E*TW%,FQ%BFD5*RTVF
M21,M,9:F*TTK3)L0$4TK4Q6F%:HDC(IC+4I%-(IDV("M-(J<K3&6F20D5?\
M#J_\5%I?_7U%_P"ABJ9%7_#H_P"*@TO_ *^HO_0Q2E\+*I_''U/=****^>/N
M3R?XY_ZS1?I-_P"R5%X-_P"1;L_^!_\ H;5+\<_]9HOTF_\ 9*A\&G_BF[/_
M ('_ .AM6]'XCCQ7P+U-NES245UGFCLTM,IP:E88M%%%(!0U+3: :!CJ6DHH
M <#2TRG!J N+1110,**** "BBB@ I"M+10 RBG8S24$B4A6EHH&-HI2*2@04
MA6EHH 913J3%4 E(12T4$V&TE/II% A"*:13J*8$9%-(J0BD*T$D=)3Z:13$
M-*TVGT$4R2,K3"*EI"M B*FD5(5IM,D;32M/*TE,5B/&::RU*5IM,DB*TW%2
ME::5IB(L4TK4A6DJB2(BFE:E*TTK020E:0BI<4QEJB2,BF,M2TTBF38A*TTB
MIBM,*T[DD16FD5*5II%,DA9:N^'A_P 5!IG_ %]1?^ABJQ%7?#Z_\3_3/^OJ
M+_T,42?NL=/XUZGMU%%%?/GVYY/\<_\ 6:+])O\ V2H/!_\ R+EI_P #_P#0
MVJ?XY_ZS1?I-_P"R5!X._P"1=M/^!_\ H;5O1^(X\5\"]3:#4ZF4M=9Y8ZBD
MS2T#N*#2TVB@H?12 TM2 4X&FT4 .HI U+0,7-.S3** 'T4@:EH&%%%% !7A
MFH?ME_#?1?C=%\*-6N=2TCQ=-<I:Q)>V3);R.Z@QE9<[2'R #T)..M>YU\/?
M\%//V9Y?B-\/[?XF^&86C\6^$4,MPUN")+BQ4[F((YW1'YP?3?[8F3:5T:02
MD[2/N&O)OC]^U!X!_9JL=(N/&VH3V[:K*\5I;V<!GF?8 6;:.BC*C/JPKC?V
M*?VGK+]H+X"V^NZK>Q1>(="C^R:_YC!=KHF1<'T5T&[/3(<=J^3OA7I=Q_P4
M$_;7U3X@:G \WPO\$2I'I\,P/ES[&)@CQT)=@TSCTPIZC,N6BMU*C3U?-LC]
M*O#^L1^(]!T_58;>XM8;V!+A(;N/RYD5E# .O\+8/([5?I](5K0PL><_'3X]
M>%/V=O!L/B?QC-=0:5->)8JUG;F9_-=78#:.V$;FN@^'/C_2/BIX'T;Q;H+R
MR:/JT N;5YXS&Y0DCE3T/%?)/_!73_DU_3?^QEM?_1%Q7M'[#O\ R:3\+_\
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M-(J4K3:9)"RTTK4Q%-9:=R;$)%7= '_$^TW_ *^8_P#T,55*U<T$?\3[3?\
MKYC_ /0A1+X6.'QKU/::***\$^T/)_CG_K-%^DW_ +)5;P?_ ,B[:?\  _\
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M !.+#_KXC_\ 0A2ELQP^)'K%%%%>,?6'D_QS_P!9HOTF_P#9*S/"W_(!M?\
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MG T%"@TZF4M(!U%(#2T#N*#2TVB@H?12 TM2 4X&FT4 .HI U+0,7-.S3**
M'T4@:EH&%%%% !1110 4444 -*TE/I"*!6&T4M)0 W%%.I"M "4444"&E:2G
MTF*=P&T444Q"%:;3Z*1(RD*T[%)5 ,Q28J3%-(H$1D4E/*TE,D92%:<124Q#
M*:RU(124$D6,4E2%::5IB(\4E/I"M,D9BK6D#_B;6/\ UW3_ -"%5ZM:2O\
MQ-K+_KNG_H0I/9CC\2/3J***\D^H/)_CG_K-%^DW_LE8OAIO^)+;?\"_]"-;
M7QS_ -9HOTF_]DK#\-G_ (DUO_P+_P!"-=.'^)GG8[^&O7_,V U+40:GJU=Y
MXI)FEIE*&H&2 TM,I0U242!J<#45.#4ADF:=48:G4%#J<&I@:EI#'TX&H\TZ
MD42!J6HPU.!H&.IP:FYHI#'T4W-.S2V&%*&I**8Q]%,S3LTABT9HHI .S17)
M_%;Q5=^!?A=XQ\26$<,U]H^C7FHV\=PI:)I(8'D4. 02I*C."#CN*^.[C]J#
M]I?P[\ K'XV:MI7PGO/!!MK749]-M'U&WU*2WEFCCV(9',2R?/W+>P<X4RY6
M-(Q<C[PI0:\A^(G[6'PO^$&@^&M4\<>)D\.#Q!:K=V5K);3W$[(45B6CA1V4
M#<!D@#/&:M>*/VI/A7X,^&6B_$'6/&5G:^$=:5&TZ_6.65KG<,X6%$,FX<[E
MVY0@A@I!IW1/++L>K45\,:A^W_K>J^#/VAO%/A"/PYK.B^!5T.;PW=FWN-MY
M%>N5D-R/-5MR@8"@1E6!##((KHKC]NB_US]GGX;>/?#ECI8UW6?%MCX6\0:7
M?1RNMA-)O$ZJJNK*WRJZ;B?E<9!-3S(U]G(^Q:*\D^*G[67PE^"?BJR\-^-/
M&EIHFMWB+)':-!-,45CA6D:-&6('UD*C )Z FO//B9^W'X7^'W[2G@GX:R75
MD=)U>V$]_K 2><H\Z?Z'%$(T*D2,8SY@++AN=OWJ?,D2HR?0^GJ**^9/"'[9
M6EZ7KGQ1_P"%F:AI7AC0?#?C(>%=+OH;:<^:61F3SV!< X1B7PB #G%.]A*+
M>Q]-T5Y9\)?VH?A=\<[C6H?!'B^UUF71D$M\K0S6QBC)8>8/.1-R?*<LN0.,
MD9&:/PV_:\^#_P 7O'-QX/\ "/CBRUCQ%")6%HL,T0F$9P_DR2(J38&6_=LV
M5!894$T70<LNQ[#32*=13)&44XK3:"=@QFFTZB@>XVBE*TE @II6G44 ,HIQ
M%-JA!2%:6B@0RBG$4E AI6FD4^@BF(BI"M2$4TB@1'13L4E,D9BD(I](5IB(
MRM-J6FE:"2,BK.D_\A:R_P"NZ?\ H0JN5JUI/_(5LO\ KLG_ *$*'L5'XD>E
MT445Y1]*>3_'/_6:+])O_9*P?#I_XD]O_P "_P#0C6]\<_\ 6:+])O\ V2N?
M\/'_ (E%O_P+_P!"-=6'^-GFX_\ A+U_S-6G!JC#4ZO0/#)0U.!J$-3PU(JY
M*#2U&&IU(8_-.S3 :6D4/S3E:HPU+2&2YIP:H@U/#4BA]+3*=F@H<&IV:CI0
MU(9)FG!JCIP:D4/HIH-.H&.#4M,I0:0#J***"KC@U+3*4&E89P_QYTZ[UCX&
M_$2PL+6:^OKKPYJ,%O:VT9DEFD:VD5410"68D@ #DDU^?%Y^PZ? OP+^%'Q8
M\(_#F75_'FAQ6]YXF\$ZQ;37!U=6&)0;:7<4E7^XJC@DA=R@']0*6H<5+<TC
M4<59'P=^TU=?$#QY\7-%ETKP?X_L_"/B3P>EI9ZEX+T*VMM<2]DN%=;._OKA
M/,L+<-M,B[T7&<[@7(X'X>?#CQU\-?A#^RUXUO\ X>>)M>C\ :CKT>N>%;/2
MY&U2+[5<R^1/';. 7V_*X(Q_ <@<C]+Z*7+K<M5;*UC\PM<\#^./'7@']L;5
M[?X5^*O#C^,9O#U[HVC7.D2BZNU%P[R,J(I#2[6$DJH6*,[!CD&MK]I3]FKQ
MMX<^)7PZUWP3HFIZEX5\3ZSHNH^)-)T^REF-AJ5IA?M3JH/EJ\<K[F( W(VX
M\K7Z2@T4N0?M7ND?FG^T5\%_%NG?M#_%G4=0T#XOZ]I7CBWM5TH_#*^6"QOE
M6W$#VNJ,T<@CC&=H9E("ESM()QZ+JG@'Q#\#_C?^S5K4?@?Q7KF@Z'X6E\/7
MJ:-$-8ETV9T"*)YHTC4HGFC,FQ 51BH.,#[GI<T^47M7LSC/A+\5++XO>&KG
M6++2-8T(6U_<:=-8Z[;+;W4<L+;6W(&; /49.<=A7P%\2O@OXO\ $%Q\1;67
MP-KFH6&I?&W3]0\HZ3-)'<Z?Y<ZR3@;,-!A@"_W?FY/-?HUX3\):1X(T9-*T
M2R6QLEDDF*!F=GDD<O)([L2SNSLS,S$DDDDFMBFXW6HHSY7='Q7\3OA#XM\;
M?M;?%^/2=)OK+3O$?PCN=&M=<>UDCLI+]Y8U2(W&-N_;G*YSM!.,"I/V8_%6
MLRK\)/AUJ7[.FM:?K'@O3YK34/&'B;3XK2STIHT6.2:PN"CF=KA@,B,H6R&R
MZ!G7[0HI<NMQ\^EK'*_#7Q]_PLCPV=7_ .$<\0>%L7,MO]@\2V/V.Z^1MOF>
M7N;Y&ZJV>1754459F%&***!#:2GTTK0*PE!%%% #:*=32*!!24M% #2*2GTA
M6G<!M%%%,5AI%)3Z0K02-II%.HI@,*TVI"M-Q0(C*TE28II6F2-QFFT^DIB&
M%:L:4O\ Q-;/_KLG_H0J$K5C2_\ D*6?_79/_0A2>S"/Q(]'HHHKRSZ0\G^.
M?^LT7Z3?^R5SOA]O^)3!_P "_P#0C71?'/\ UFB_2;_V2N:T'_D%0?\  O\
MT(UUX;XWZ'F9A_"7K_F:H-.!J)6IP->@>$2@T[-1!J>&H&2 TY6J*G!JFQ1-
MFE!J(-3PU(HDH!IE.!H'<?2AJ93@:DHD#4ZHJ<&I#) U+3 :7-!0^ES3:*0R
M0&G U&&I:11*#13 :<&H&.I0:;12&/HI U+2&%.!IM%,8^BFAJ=4C"E#4E%
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MG4REI%$@:E!J/-.!I#)**;FG T%"@TZF4M(!U%(#2T#N*#2TVB@H?12 TM2
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90HD4DE#@<UUM%'M7V&L.D[W"BBBL#K/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  M LH# 2(  A$! Q$!_\0
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M .!4?^-<QN%&11[*(?6*GE_7S.G_ .$NT+_H-:?_ .!4?^-'_"7:%_T&M/\
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M /P*C_QKEO*I/)H]E$7UBKY?U\SJO^$NT+_H-:?_ .!4?^-'_"7:%_T&M/\
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M (T?\)=H7_0:T_\ \"H_\:X[[./2C[./2CV,!?6JO9'8_P#"7:%_T&M/_P#
MJ/\ QH_X2[0O^@UI_P#X%1_XUQGV44?911[& ?6JO9?U\SL_^$NT+_H-:?\
M^!4?^-'_  EVA?\ 0:T__P "H_\ &N+^RBD^RBG[& ?6JO9?U\SM?^$NT+_H
M-:?_ .!4?^-'_"7:%_T&M/\ _ J/_&N)^RTGV04>QAW%]:J]D=O_ ,)=H7_0
M:T__ ,"H_P#&C_A+M"_Z#6G_ /@5'_C7#_9*3[)[4>QAW#ZW5[([G_A+M"_Z
M#6G_ /@5'_C1_P )=H7_ $&M/_\  J/_ !KA?L?M2?8_:CV,.XOK=7LCN_\
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M.E^U-_LO_9I_58=Q?VC6_E1[+_PEVA?]!K3_ /P*C_QH_P"$NT+_ *#6G_\
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M%UN?3[ZRN+B[O4O85EDA299XTA* /ARDF2PRHVDMZGX+\?>.O'_C'6[O3/\
MA';;P?HWB&XT&?3;N"?^T)D@4+)<K<K(8T/FGY83"<HN3*I;Y;$?P+\!1^&]
M8T'^Q&;2M7T^STN^A>^N&::VM8_+MT+F3<"J<;@0S=6)/-6;CX-^"[OQF/%$
MFES'4_MB:DT*W]RME)>(@1+F2S$GV=YU54Q*T9<%$(.44@Y)![6!\_:'\?-7
M\#? 7P;'X1BT+1;UM"U+5ET>/0=6UPMY-PRHFV*4?9H68G=<7$^T$X"X#%?3
M/V<?% \9?%#XH>(/(^R_VM:^';_R-V[R_-TQ'VY[XW8_"N@NOV<?AQ>:?I-B
M^A3)9Z;9S:=%;P:I>1)+:RR>9);W 24"YB9^?+FWKR>.374>!_AWX:^')N3X
M?TYK%KBWM+29GN9IB\=K"(( 3(['*QJ%SU;JQ)YI*$NHW6A9V/G'XC+X3L_V
MA_B_K7BSX-3?%>QTO1-%N&FM]*TW4)-/C$=T7Q'=3)(=P .(5;/E\XP,L\-_
M&#QC\+/ OPY\!:3-:7^IKX1_MXZE%HNI^*H9(7E*V=I$;$AMH3"FY=BN$7:K
M[N/J+3?#.CZ3XHUGQ%:6GE:SK$5O#?7/FN?.2 .(1M)VKM$C_= SGG.!7$7/
M[-_PYN-)L]-CT:\L+6S%S';G3=:OK.2*&X</-;K)#,KBW9@#Y&?*&!A!@4<C
MZ#5:+T9Q,G[1WC:'Q3X?NM;T&+P!X5U"+1I3#XBT+4)2_P!L*K.CZC"?)LIH
M97\H0W,*[V"?.HES'KW/[0/B"&UOI!9:9N@^)MOX,7,4F#922PHTA_>?Z[$K
M8;[O ^6NJF^ /P^DU:WODT%K,0BT']GV-_<VVGS?90BVQFLXY%MYC&L<2J9(
MV($48Z(H"W_P"\ :GXND\27&CSMJ<FIP:VR+J=VEI]OA$8CNQ:K*(1,!$BF0
M)N9058D,P)RR#VD#YQ_9MU_QQI^I^!+;0[Z'4M+C^'FKZA#X9D$D2WETFH[8
MP93-Y:.SL@$IC.U-ZX.[<OO/[/?Q>USX@76J:7XKN;&/6[>QL]0&F_\ "/:A
MH-];K-YBR+):W;2>8BO&5$\,KHQWC"[07VK/X$> +*#28(M!_P!%TO3KS28+
M9[R=X9+.Z.;BWGC,A6XC8\[90X! (P:TO ?PM\,?#>XN;G1;>_:[N(([5[O5
M=6N]2G$,98QPK)<RR,D:EV(12%RQ.,T*+02J1E<X*3P;X=^+O[1'CK3/'&EV
M7B>Q\.Z7I@TG1-8MUN;.%+GSFENE@<%#*[Q>7YA!95B*@@.P;*_X3K5O#=W_
M ,*\^%NO:3J\7AW0;W6)M5\4/)J6_P N[D@CTX/#+$4,;1R1M*YD:-8HPR2,
MQ:O4_&GPK\+^/M6L]6U.WOK?5[2![6+4]'U6[TN[$#LK-"TUK+&[1ED5MC,5
MRH.,\UEZM\ ?A]K.C:1I3Z$UC8Z59R:=:II-]<V#?9)"IDMY'@D1I8G*JSQR
M%E8@%@3S1RL/:1ZGG6J_M >-?%\F@3>"4\/Z)9:E\/E\=,VOV,]](N[:5M0(
MIX1R)%S)DXVGY6W?+RGPS\:7.O\ Q@\?_%G7;/2+VWTOX=Z'K=E:KIQ-]9Q7
M$%[<&"&Y>8A!\DH<A!YFZ/[OE_/]'W'PY\+W.JMJ+:5&ET=';0 89'C1;!F#
M&!44A5&0,$ $8P"!47A/X6^$_!$ER^C:2MJ;G2[+1IEDFDF5[.T21+:(B1F&
M%6609ZMN^8M@4N5C]I&VA\XQ_M;?$*S\!ZMKTWAN+4,^'XM:M;J3PMJ^DV%C
M.UQ ALI9[KBZW)/N2:'8#Y+GR\$5L^-OVC/B'X-\7>(?#UMIUOXIU'PG;VDU
M[;Z)X+U>Y;7))LRF&!X)9H[ B'8JM.TN]R3M517I]G^S+\,['3]0L5T&>:TO
M+)--,-UJU[<"WM%D646UMYDS?9H=Z(?+AV*?+3(PJXUO&WP-\#?$36GU77M(
MDNKJ:**WNUAU"YMX+^&-R\<5W#%(L=U&I9L),KKAF&,,03ED/GI]CRV/X]^/
M/^$FGOY8_#T?A.#Q_%X).F_8+C^T)%E9%6X-P;C8C*TR9C\ILA&.Y=P"]#X'
M^+?C77/ 5U\3]0AT!_ S:?J.H1Z-:PS1ZG:QV[/Y.;@R/%.SK$=R^7%L+@!G
MV_-WTGPC\(21RHVDY277T\3N/M,W.I(R,L_W^QC0[/N<?=ZU4T;X&^!M!\2M
MKEGH[B[S<M%;3WUQ-8VS7!)N'@M'D:"!Y"S[FBC4MYD@)P[9+2%S0['G_P"S
M]\<O&'Q(\165GKVB32:;J>B#5X]2M?"NJ:3;:=-N3-F\]X-EV664,DT6P'RG
M.P C&E\1/#^E?$;]HGPWX/\ %=M#JWAF#PW=ZS!H=\@DLKZ[%Q#"9)HF&V;R
M4D&U7!"F;>!N52.Q\ _!/P7\,M4;4?#VF3V]W]D&GPO=:C=7@M+4,&^SVRSR
M.MO#N"GRX@BG8G'R+C4\=?#GP]\1X]._MRTG>YTV9I[&^L+Z>QO+1V0HYBN+
M=TECW(S*P5@&!P<BBSMJ'-&]T>2^)/$6D_ O3T\+> _$EA;276O31'29=*O-
M??1P;07#6EIINGJLHC V2;7=%B68D$KY<=?/'CSXA7_Q8\/W/BK5;.&PU2^\
M!Z<+N"!2L:S1^)!$Y52S%5+1DA2S$ XR<9/V%<?L]^ KC1=+TT:7>6R:;>3:
MA!>6>L7MO?&XF5EGEDNXYEGE:0,0YD=M_&[.!BO:_LT_#.RT@Z7;^&$@T[['
M]@%M'>7"HEO]L-Z(E D^51<,6 &,#"#" +2Y9%*<%J>H^37PYI?CBX^"GCGX
MRZK9JS3^+M2U2RTN-F'EOK=O-%%:1X^]NF^W(#C/RVW3/7[+\/Z-+HMUK<TN
MHW%\NHWQO(XYI'=;53%''Y4>]VVKF,OA<+ND;"C-<]??!7P/J5Q9SW6@Q3S6
M?B#_ (2FW>2:4F/4L$?:!\WH?N?<Z';D"J:;(BXK<^;_ (/Z]<? KX*Z=X4T
M'5K6VN/^$V\1:1!->Z)J.NW4D5M>W>6CLK+][*V(UW.TB*@))+'"G;T;]J[Q
M1-\.[/6=2TK2(-7USPR]QH-KY<L:3ZU%??8);>3,C?NWFN+%E4,&"O*"S8W#
MVS5/@+X'U:SM[>33+NU^SZI>:S#<:?JUY9W$=U=O(]TPFAE20+(TK[H]VPY
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M;_"E\OQI_P!"G??]^V_PKZ;HH^MS#^S*/=GS)Y?C7_H4K[_OV_\ A2[?&O\
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M?\)!X^_Z$ZX_[\R5]"T4?6'V0?48?S/[SYZ_X2'Q]_T)UQ_WYDI?^$B\??\
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M\_\ _"5>/_\ H3)O^_,E'_"5>/\ _H3)O^_,E?0%%'UA]D'U*/\ ,_O/ /\
MA*O'_P#T)DW_ 'YDH_X2KQ__ -"9-_WYDKW^BCZP^R#ZE'^9G@'_  E7C_\
MZ$R;_OS)1_PE7C__ *$R;_OS)7O]%'UA]D'U*/\ ,SP#_A*O'_\ T)DW_?F2
MD_X2GQ__ -"7-_WYDKZ HH^L/L@^I1_F9\__ /"4^/\ _H2YO^_,E'_"4^/_
M /H2YO\ OS)7T!11]8?9!]2C_,SQCX=CQ)JOQ"M]1UG09]*BALY(1(T;!#D@
5@<]^M>ST45C.;F[LZZ-)48\J/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140358901555200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RadNet,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000790526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3326724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1510 Cotner Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los
  Angeles<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-7808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RDNT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>radnet_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rdnt-20230509.xsd" xlink:type="simple"/>
    <context id="From2023-05-09to2023-05-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000790526</identifier>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-05-09to2023-05-09">0000790526</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-05-09to2023-05-09">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-05-09to2023-05-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-05-09to2023-05-09">2023-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-05-09to2023-05-09">RadNet, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-05-09to2023-05-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-05-09to2023-05-09">001-33307</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-05-09to2023-05-09">13-3326724</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-05-09to2023-05-09">1510 Cotner Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-05-09to2023-05-09">Los   Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-05-09to2023-05-09">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-05-09to2023-05-09">90025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-05-09to2023-05-09">310</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-05-09to2023-05-09">478-7808</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-05-09to2023-05-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-05-09to2023-05-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-05-09to2023-05-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-05-09to2023-05-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-05-09to2023-05-09">Common     Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-05-09to2023-05-09">RDNT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-05-09to2023-05-09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-05-09to2023-05-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MYQ; /]I!NMWX,W-W-"3A2Q *KGI@V'J_P=T/K,J*3>5"6=BB%H=KSN U<!?
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 0HRJ5I>*NQS
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M4$L! A0#%     @ 0HRJ5@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !"C*I6Z>1A6^\    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !"C*I6F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( $*,JE8!L"UM100  '(0   8
M      " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !"C*I6GZ ;\+$"  #B#   #0              @ &)#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( $*,JE:7BKL<P    !,"   +              "
M 64/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $*,JE:JQ"(6,P$  "("   /
M              "  4X0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !"
MC*I6)!Z;HJT   #X 0  &@              @ &N$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !"C*I699!YDAD!  #/ P  $P
M            @ &3$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"  #=$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="radnet_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://radnet.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="radnet_8k.htm">radnet_8k.htm</File>
    <File>radnet_ex9901.htm</File>
    <File>radnet_ex9902.htm</File>
    <File>rdnt-20230509.xsd</File>
    <File>rdnt-20230509_lab.xml</File>
    <File>rdnt-20230509_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "radnet_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "radnet_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rdnt-20230509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rdnt-20230509_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rdnt-20230509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "RDNT",
   "nsuri": "http://radnet.com/20230509",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "radnet_8k.htm",
      "contextRef": "From2023-05-09to2023-05-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://radnet.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "radnet_8k.htm",
      "contextRef": "From2023-05-09to2023-05-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001683168-23-003132-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-23-003132-xbrl.zip
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M!C ?,( M&N/7[ Q M"44;KE;\[+98GK]E2VAG93_G) G5E&"F8;0;R#QTRG
MC=4H2^D#+%&ZYJ>H<(3(F+&FD_XX_%@$O5_NZT.*W6+Z/[]Q\LREH.9(@9U6
M;>.^;)*](XNDF:.%H%VK:+76'=MY4A(KJIXU)8']T"9*;5YJ8 M"U+HJIL*R
M\4$5W4%MPHM@J,CJB7XS9JM&O(E,'8LDE2HA&<AJF0B,%*@[XW!M:YWGE];+
M]18O*!C0HR@Z+]E;U$R"_@WM1/=OV^FDORX-O^/(L@SS:4'!)F 9[D1/V+!D
MD5=<2D)7-PUZ9DD!K]@=)N081RD99\%)!?><I<R S7"?;!$)R"GCDU-@<,T
MNT9W=SL6V(6*O:M9T:08L<6]:?5+A?DR_55836Q?;>[(OC5)RUM8-[0GPLY^
M>[? TL#L8X4?@Z5\-FJTI#"=W*CFT_H8.6J:C;!#@!<J/EZXD!4,6!"P$4WX
M;YTOA7+/Q'?\.ZOK.:!D4XA-9C(9)O>LFOY@='R.9CD?S;K\I.YL@HF4T9\C
M(,[_OGHP[RXO1MEWIF ,V(D2FP%J<B<Y+OL2/>&;L8J:74QN7F-FJ:Y!FH$T
M:X -] !QGRG)-#(\$PQGTQ41"RQ[5=1A)!MME#<WCXN*-AS*)BDC0T1JD4WG
MK5CJ:Y95;W=0;:@KVA0([.=DU-!2AU&,FJ9^RKIVZ>CW$R95F+F)LDK@**(D
M>Y+*'6]3=NDM0%[-*5QZ08XV%S5%X743 R\YO_F<Q)?]/[_>)[)FJZH7A-.9
M(YN/]NVJ/MM0EB0#FZ;SXTI6,1MM%[3OPY^#_F^9>QRL(2\?.SEH]V.6017-
M4D%JRD]8'2WD?85M=O;3G$?#C5Y"G*?G0D9D 5HM;^0CZ9>-HE\%?FT:76VL
M1E.O/F:__<R/QM_U=>RJQ$R=*%UI)EET6>UCA50\1-+M*)0<BV1):B&;1@N\
M=S"!,7'&=;5S<ONE56M>Y=\N:(@&,%&J /%@,%7FE^18UYRZK$'W-.)Y=TV,
ME(O">DN#Y2N_9#T^MNNT?Y>O[Z8W#U?9=?.2;_9$"0)1[O@E7*Y+/*.P=N#
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M3#^S:\"+[@#P2)!%.21FPO*C8J'8^$!SSB39SZPW,".JE2I?8H[#@[1)4&;
M'&IY_APEMI<EVU.@6O?W+K_7?,Y&KJ-S(W !]1X<*\ 7)[2JXGO2ICUMR(]U
MH8F,7SD\2+[31$5LDM_/Q($]"FQ1AQ9FGRO-K'Y@6<>H"PH!=Q]:5Q:HI9:'
MFG4D76)6UN'!?#O/)=ML\3&GF[GBOP2EI2S>3F2)=59GWL46LZXI9K@$P$:_
MN.JRUN6W]D6[J[ S> !8JVUJ"ONA/;&F(ACJK[:A>8//8$K0T2I@AN@%=G39
MZIZW_O6)W9Q?]CXH:/FR-*>3%$P:L\D(!WY@<<T 6@59 Q3_8)(Z-3#O!\=
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MCC.-E/<\@14Q;)@)1.1Z)C F \X+SB?)PN'$$5*P#'D@8F$<P *&DE@36.S
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M18CX\?3J_$^*]WWO_;@X^?]02P,$%     @ 0HRJ5EI%+[AB4P  ^,(! !$
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MS]ECJ=+OQ6")P<=OSF*DKUA*]/%1MT'EITF-I6M]Y)7>A/6Z*T/1S8!S$X1
MTY6"S^W OFJ@CC/R:M58V/#;5?"_*+]"(HYISGHG/% "SJJ7FI:87>9BJP6A
MK0%*;B<X)AV8D)V,H/O=SU39[T2MLX>\\R10 T/;K5Z5X.%952(]J7ER#L='
MC4C00O1_N+QGYA8>& F53W$*43>+^$41A-XW?R.0%WS2U)/ADC9UH'KG:X>9
M:]EKL5IEW"0T#7P<L2]<,A5M))3SO$_7"DOT$>:];84YZ-;Y7..)7EG,U$_'
M@AW YK%D1ZE&J$IVU#+B^IB8SZ. ?(1I12%MM%FV)T659@S6J]7%="5Y"^*&
M!RN7,!U:..9]17G"C!4BWI>/&2[4?5F'V)&G2 11^S 16,W@[0&- #:7>^\Q
M!ICH536-"Q[A6Q5UA3'0NI&EAJ*X.SZ;!#51%].'EC-;"M?+W$Q%>&W9#V?G
M$!OMJO'U:^.@O5=#(D'84*\N=3UXXY41 )[A4"T:"?;>T]/IIV+0RGZKHC9/
MFY4W^EFY+R=?I]O2B[U[9T\?A>=KIEA36V .B8]-[=2F0BDG; 6H9<%;G;8$
M-YRO)LI<>("/IH_Q=&QN!X\#Q3-T0U-29UI:.D@Y\C9'B#JMUWEKZ096RZ1*
M0.R5Z?TP?0DLMS$V+!<PM+9)FJR=:+<:2?#5MOFFX&Y3PH/=T1 MU;,_C&3W
MMY;'!A1(^XM<P,B1SA/@U56]U#(V^G.NH]++-8IJ-4 1<J\J ]QL0F*=!?'L
MM:AYDK]%.0;#5(:17(X?O7(9)6<#-<6I4\D*E%6UA55C-BALFL NY 3@;^D5
MU2BK<E R.3%;-R7018F$T+I;+GV6J9W'7K&"&&(:/[.8:'@0>5D:%NVHLEJ>
MKR@#FOP[2 ^AX06(G12+X_4IS%75\._RFE;V"Z%TT)9\!ZYU*R-;N77CBFM3
M&2RWQG0_S:R-R=RSZHC:H[F@^&[>,1.=;,;K457M<^ZB^/M,H\NJ.34[L>J6
M7D_G-6@HTD9#C#%O\L2G&SIT$X>XZ!QY#2D3+I ?F1+O<B,WGUAF-Q*$X+N)
M8JH32] =/+?N&MH!9G@Q=7.BEG>*,^=Y6EJ21=:U? 6Y*$S9)3%Z(Q^03G[:
M01C'R5T]BM-(3O'2"C$5,.EV$!<:S<93*DVFBL!)F_[2QT 1YH$_ !,1)3U
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MG.A BH>K=4GNA#$I \)LTW=64BE7*^OJ$,D7LJLR67L"_R[N<=GF+1TXL/
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MKD"MB;4W8PG1CHS*7(COX#06,A8K*4< DH'0O@N8SMQ9.;_WC?B2'$V]SCK
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MO8J=FZ!>&UBKT$2FC<EZ#1O<2=A[ZYM]*#"DSG0\T;__!"8=ZHA\Z69_U<D
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MT]Y%Z?Z,*-V3/S1*]T?'S (A_O79JQ<_?8$?_O[VNV^_^#]02P,$%     @
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M"(N4<G/<;<S_WOM=1(G/+\'\T(\->T07K ??U (-)U?3R]]02P,$%     @
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M[??+ZYNNY2>Y66^2?ZUP2N26_P)02P,$%     @ 0HRJ5K6;;>)4!P  T5<
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M;MKB&_?+O7_5;OD?4$L! A0#%     @ 0HRJ5JY($AO %   **    T
M         ( !     ')A9&YE=%\X:RYH=&U02P$"% ,4    " !"C*I6,&5&
MH-X_   />P( $0              @ 'K%   <F%D;F5T7V5X.3DP,2YH=&U0
M2P$"% ,4    " !"C*I66D4ON&)3  #XP@$ $0              @ 'X5
M<F%D;F5T7V5X.3DP,BYH=&U02P$"% ,4    " !"C*I6,]4SN"@#  "E"P
M$0              @ &)J   <F1N="TR,#(S,#4P.2YX<V102P$"% ,4
M" !"C*I6+1IA2_X*  " A@  %0              @ '@JP  <F1N="TR,#(S
M,#4P.5]L86(N>&UL4$L! A0#%     @ 0HRJ5K6;;>)4!P  T5<  !4
M         ( !$;<  ')D;G0M,C R,S U,#E?<')E+GAM;%!+!08     !@ &
+ 'X!  "8O@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
